Casaso

Republic of Iraq Ministry of Higher Education and Scientific Research University of Kerbala College of Science Department of Chemistry



Synthesis and studies of biological activity of -1,3oxazepine-4,7-dione derivitives "

A Thesis

Submitted to the Council of the College of Science, University of Kerbala in Partial fulfillment of the Requirements for the Degree of Master in Chemistry.

Ву

Sawsan KhdeaurAbbas

B. Sc. Chemistry, College of Science Babylon University (2002)

Supervised by

Asst. Prof. Dr.Zeid Hassan Abood Al-a' arajy

1435 A. H

2014 A.

(A~#~+~



<u>(025200)</u>

<u>neres</u>

6

Certification of the Supervisor

I certify that this thesis was prepared under my supervision in the Department of Chemistry, College of Science, University of Kerbala in partial fulfillment of the requirements for the degree of Master in Organic Chemistry.

Signature :

Name : Dr. Zeid Hassan Abood Title : Asst. Prof. Address : Department of Chemistry College of science Kerbala University Date: / /2014

In view of the available recommendations, I forward this thesis for debate by the examining committee Certification of the Supervisor.

Signature: Dr. Baker Abdl- Zahra Juda Head of the Chemistry Department College of Science Kerbala University Date : / / 2014

~~~~

<u>Uner</u>

# S ( The second sec

# Certification of Scientific expert

I certify that I have corrected the scientific content of the thesis entitled " Synthesis and studies of biological activity of -1,3- oxazepine-4,7-dione derivitives "therefore it has become qualified for debate.

Signature : Name : Majed Jari Mohammed Title : Asst. Prof. Address :Kufa University/College of Science Date : //2014

# Certification of the Examining Committee

We certify that after reading this thesis "Synthesis and studies of biological activity of -1,3- oxazepine-4,7-dione derivitives " and examining the student " Sawsan Khdeaur Abbas" in its contents, We found that it is adequate to award her the degree of master of Science in Chemistry.

### <u>Chairman</u>

Signature : Name : Dr.Mahmood shaker maktof Title : Professor Address :Thi-Qar University / College of Science Date : / / 2014

# Member

Signature : Name : Dr.Mohammed Nadem Bahjet Title : Asst.Prof. Address : Kerbala University/ College of education for pure Science Date : / /2014

# Member

Signature : Name : Dr.Naji Mosa Ali Title : Asst.Prof. Address :Kufa University/ College of Pharmesy Date : / / 2014

### <u>Member (Supervisor)</u>

Signature : Name : Dr. Zeid Hassan Abood Title : Asst. Prof. Address : Kerbala University / College of Science Date : / / 2014

Approved by the Dean of the College of Science Name : Prof. Dr. Ahmed Mahmood Abd Al-latif Signature :

Date: / / 2014



ଚ

# Read

2223

2

Uner

# Certification of Linguistic expert

This is to certify that I have read the thesis entitled "Synthesis and studies of biological activity of -1,3- oxazepine-4,7-dione derivitives " and corrected its grammatical mistakes, therefore it has become qualified for debate.

Signature :

5

( Correction of the correction

Name : Sabah Wajed Ali

Title : Asst. Prof.

Address : Kerbala University / College of education Date : //2014

### <u>naan</u>

# Acknowledgements

First of all great thanks to **Allah** for the uncountable gifts and for helping me to accomplish this thesis.

After I have finished the writing of my thesis, It gives me a great pleasure to express my sincere gratitude and admiration to my supervisor **Asst.Prof. Dr. Zeid Hassan Abood** for suggesting the problem, his continuous guidance, and fruitful discussions have immensely contributed to the completion of the present work. Again I thank him so much and wish him a good health and luck.

My Sincere thank are due to the University of Kerbala, the Dean of College of Science and to the Head of Chemistry Department.

I would like to express my sincere thanks and my appreciation to **Mr. Hassan** Ali and his wife for their help *L* support wish them all happiness and luck;

I also owe a special debt to Asst.prof. Dr. Ali Abdl-Kadam Jassim and Mr. Salah Hashim for their help to measurement the biological activity of prepared compounds and Mr. Hussain Mubark for their help during my work.

To the jewel, my real friend, Shamma Ibrahim, who has been really a great friend and sister in helping me and for her warm feelings, I wish her more success.

I'd like to thank my dearest friend, who has been with me all the time and for warm feeling and helping. Finally I'd like to thank my friend **Sara** For her help, for her love.

Sawsan

 $\mathbf{0}$ 



### Abstract

In this work two series of new bisazo bis-1,3-oxazepine - 4,7- dione  $[A_7-A_{18}]$  and bis -1,3-oxazepine -4,7-dione  $[B_6-B_{15}]$  derivatives have been synthesized via [2+5] cycloaddition reaction of phthalic and maleic anhydrides to some synthesized bisazoimine  $[A_1-A_6]$  and bisimine  $[B_1-B_5]$  derivatives.

In the first line, *o*-Toludine was converted to the corresponding bis-azoaldehyde [A] via coupling reaction with derivative phenoxide anion of 2hydroxybenzaldehyde . Aldehyde groups in bis-azoaldehyde derivative [A] was condensed with different primary amines a one hydrazine (cyclohexyl amine, phenylhydrazine, 2,4-dimethylaniline, 4-methoxyaniline, aniline and 4bromoaniline) in presense of glacial acetic acid as a catalyst in absolute ethanol to give bisazoimine derivatives  $[A_1-A_6]$  respectively. The resulting bisazoimine derivatives [A1-A6] were then introduced in [2+5] cycloaddition reaction with each of phthalic anhydride and maleic anhydride in dry benzene to give new bis-1,3-oxazepine-4,7-dione derivatives [A<sub>7</sub>-A<sub>12</sub>] and bisazo  $[A_{13}-A_{18}]$ respectively as shown in scheme (I).

In the second line , *o*-Toludine was directly condensed with different benzaldehyde derivatives (2,5-dimethoxybenzaldehyde, 4-chlorobenzaldehyde, benzaldehyde, 2-hydroxybenzaldehyde and 4-*N*,*N*-dimethylaminobenzaldehyde) in presense of glacial acetic acid as a catalyst in absolute ethanol to give bisimine derivatives [B<sub>1</sub>-B<sub>5</sub>]. The resulting bisimine derivatives [B<sub>1</sub>-B<sub>5</sub>] were then introduced in [2+5] cycloaddition reaction with each of phthalic anhydride and maleic anhydride in dry benzene to give new bis-1,3-oxazepine-4,7-dione derivatives [B<sub>6</sub>-B<sub>10</sub>] and [B<sub>11</sub>-B<sub>15</sub>] respectively as shown in scheme (II).

All the synthesized target compounds  $[A_7-A_{18}]$  and  $[B_6-B_{15}]$  have been characterized by (C.H.N.) elementary micro analysis and the spectroscopic methods including FT-IR ,<sup>1</sup>H NMR for compounds  $[A_7, A_8, A_9, A_{10}, A_{11}, A_{13}, A_{14}, A_{15}, A_{16}, A_{17}, B_7, B_8, B_{11}, B_{12}, B_{13}$  and  $B_{15}]$ .

The last step included preliminary evaluation of antibacterial activity of all target compounds  $[A_7-A_{18}]$  and  $[B_6-B_{15}]$  which were tested against *Staphylococcus aureous* (Gram positive) and *Escherichia coli* (Gram negative), these activities have been determined in *vitro* using disc diffusion method (Agar), the results revealed that some of compounds showed measurable activity as shown in table (3-7).





### Abbreviations

| Symbol                    | Name                              |
|---------------------------|-----------------------------------|
| h                         | Hour                              |
| Ar                        | Aryl                              |
| DMSO                      | Dimethyl Sulfoxide                |
| Ph                        | Phenyl                            |
| Abs.                      | Absolute                          |
| $\mathbf{R}_{\mathbf{f}}$ | Retention Factor                  |
| TLC                       | Thin Layer Chromatograghy         |
| M.f.                      | Molecular Formula                 |
| M.Wt.                     | Molecular Weight                  |
| T.S                       | Transition State                  |
| FT-IR                     | Fourier Transform Infrared        |
| <sup>1</sup> HNMR         | Proton Nuclear Magnetic Resonance |
| Δ                         | Heat                              |
| Et                        | Ethyl                             |
| Me                        | Methyl                            |
| М.р.                      | Melting Point                     |
| Et <sub>2</sub> O         | Diethyl ether                     |
| EtOAc                     | Ethyl acetate                     |

| Str.vib. | Stretching vibration  |
|----------|-----------------------|
| δ        | Bending in IR         |
| δ        | Chemical shift in NMR |
| 0.0.p.   | Out of plane          |
| ppm      | Part per million      |
| R.t.     | Reaction time         |
| br.      | Broad                 |

### Contents

| No.                       | Subject                                    | Page |
|---------------------------|--------------------------------------------|------|
| Chapter one: Introduction |                                            |      |
| 1.1                       | Azo Compounds                              | 1    |
| 1.2                       | Synthesis of Azo Compounds                 | 2    |
| 1.3                       | Isomerism in Azo Compounds                 | 3    |
| 1.4                       | Importance of Azo Compounds                | 4    |
| 1.5                       | Schiff bases                               | 6    |
| 1.6                       | Synthesis of Schiff bases                  | 7    |
| 1.7                       | Reactions of Schiff bases                  | 10   |
| 1.7.1                     | Addition reactions                         | 10   |
| 1.7.1.1                   | Addition of alkyl halides                  | 11   |
| 1.7.1.2                   | Addition of carboxylic acid chlorides      | 11   |
| 1.7.1.3                   | Addition of maleic and succinic anhydrides | 12   |
| 1.7.1.4                   | Addition of Grignard reagents              | 12   |
| 1.7.1.5                   | Addition of hydrogen                       | 13   |
| 1.7.2                     | Cycloaddition reactions                    | 13   |
| 1.7.2.1                   | Formation of three-membered rings          | 14   |
| 1.7.2.2                   | Formation of four- membered rings          | 14   |

| 1.7.2.3                                                        | Formation of five-membered rings                                                                                                                                                                                                                                                                                                                                                                                                                                | 15                                           |
|----------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------|
| 1.7.2.4                                                        | Formation of six-membered rings                                                                                                                                                                                                                                                                                                                                                                                                                                 | 15                                           |
| 1.8                                                            | Schiff bases uses                                                                                                                                                                                                                                                                                                                                                                                                                                               | 15                                           |
| 1.9                                                            | Pericyclic reactions                                                                                                                                                                                                                                                                                                                                                                                                                                            | 16                                           |
| 1.9.1                                                          | Electrocyclic reactions                                                                                                                                                                                                                                                                                                                                                                                                                                         | 16                                           |
| 1.9.2                                                          | Cycloaddition reactions                                                                                                                                                                                                                                                                                                                                                                                                                                         | 17                                           |
| 1.9.3                                                          | Sigmatropic rearrangements                                                                                                                                                                                                                                                                                                                                                                                                                                      | 17                                           |
| 1.10                                                           | Synthesis of 1,3- and 1,4-oxazepines                                                                                                                                                                                                                                                                                                                                                                                                                            | 18                                           |
| 1.11                                                           | Importance of oxazepine                                                                                                                                                                                                                                                                                                                                                                                                                                         | 23                                           |
|                                                                | Aim of the Study                                                                                                                                                                                                                                                                                                                                                                                                                                                | 26                                           |
|                                                                | Chapter two: Experimental part                                                                                                                                                                                                                                                                                                                                                                                                                                  |                                              |
|                                                                |                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |                                              |
| 2.1                                                            | Chemicals                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 27                                           |
| 2.1<br>2.2                                                     | Chemicals Instrumentations                                                                                                                                                                                                                                                                                                                                                                                                                                      | 27<br>29                                     |
| 2.1<br>2.2<br>2.3                                              | Chemicals<br>Instrumentations<br>Synthesis methods                                                                                                                                                                                                                                                                                                                                                                                                              | 27<br>29<br>30                               |
| 2.1<br>2.2<br>2.3<br>2.3.1                                     | Chemicals<br>Instrumentations<br>Synthesis methods<br>Synthesis of 5,5'- ((3,3'-dimethyl-[1,1'4, biphenyl] 4'-diyl)<br>bis (diazene-2,1diyl)) bis (2-hydroxybenzaldehyde) [A]                                                                                                                                                                                                                                                                                   | 27<br>29<br>30<br>30                         |
| 2.1<br>2.2<br>2.3<br>2.3.1<br>2.3.2                            | Chemicals         Instrumentations         Synthesis methods         Synthesis of 5,5'- ((3,3'-dimethyl-[1,1'4, biphenyl] 4'-diyl)         bis (diazene-2,1diyl)) bis (2-hydroxybenzaldehyde) [A]         General procedure for Synthesis of bis-azoimine derivatives         [A1-A6]                                                                                                                                                                           | 27<br>29<br>30<br>30<br>31                   |
| 2.1<br>2.2<br>2.3<br>2.3.1<br>2.3.2<br>2.3.3                   | Chemicals         Instrumentations         Synthesis methods         Synthesis of 5,5'- ((3,3'-dimethyl-[1,1'4, biphenyl] 4'-diyl)         bis (diazene-2,1diyl)) bis (2-hydroxybenzaldehyde) [A]         General procedure for Synthesis of bis-azoimine derivatives         [A <sub>1</sub> -A <sub>6</sub> ]         General procedure for synthesis of bisazo bis-1,3-oxazepine-         4.7. diagonal procedure for synthesis of bisazo bis-1,3-oxazepine- | 27<br>29<br>30<br>30<br>31<br>34             |
| 2.1<br>2.2<br>2.3<br>2.3.1<br>2.3.2<br>2.3.2                   | Chemicals<br>Instrumentations<br>Synthesis methods<br>Synthesis of 5,5'- ((3,3'-dimethyl-[1,1'4, biphenyl] 4'-diyl)<br>bis (diazene-2,1diyl)) bis (2-hydroxybenzaldehyde) [A]<br>General procedure for Synthesis of bis-azoimine derivatives<br>[A <sub>1</sub> -A <sub>6</sub> ]<br>General procedure for synthesis of bisazo bis-1,3-oxazepine-<br>4,7-dione derivatives [A <sub>7</sub> -A <sub>12</sub> ]                                                   | 27<br>29<br>30<br>30<br>31<br>34             |
| 2.1<br>2.2<br>2.3<br>2.3.1<br>2.3.2<br>2.3.2<br>2.3.3<br>2.3.4 | Chemicals         Instrumentations         Synthesis methods         Synthesis of 5,5'- ((3,3'-dimethyl-[1,1'4, biphenyl] 4'-diyl)         bis (diazene-2,1diyl)) bis (2-hydroxybenzaldehyde) [A]         General procedure for Synthesis of bis-azoimine derivatives         [A1-A6]         General procedure for synthesis of bisazo bis-1,3-oxazepine-4,7-dione derivatives [A7-A12]         General procedure for synthesis of bisazo bis -1,3-oxazepine-  | 27<br>29<br>30<br>30<br>31<br>31<br>34<br>37 |

| 2.3.5                                 | General procedure for Synthesis of bisimine derivatives [B <sub>1</sub> -B <sub>5</sub> ]                           | 41  |  |
|---------------------------------------|---------------------------------------------------------------------------------------------------------------------|-----|--|
| 2.3.6                                 | General procedure for synthesis of bis-1,3-oxazepine-4,7-<br>dione derivatives [B <sub>6</sub> - B <sub>10</sub> ]  | 43  |  |
| 2.3.7                                 | General procedure for Synthesis of bis -1,3-oxazepine-4,7-<br>dione derivatives [B <sub>11</sub> -B <sub>15</sub> ] | 45  |  |
| Chapter three: Results and Discussion |                                                                                                                     |     |  |
| 3.1                                   | Synthesisof5,5'-((3,3'-dimethyl-[1,1'-biphenyl]-4,4'-diyl)bis(diazene-2,1diyl))bis(2-hydroxybenzaldehyde) [A]       | 48  |  |
| 3.2                                   | Synthesis of bis-azoimine derivatives [A1-A6]                                                                       | 50  |  |
| 3.3                                   | Synthesis of bisazobis -1,3-oxazepine-4,7-dione derivatives [A <sub>7</sub><br>-A <sub>12</sub> ]                   | 54  |  |
| 3.4                                   | Synthesis of bisazobis -1,3-oxazepine-4,7-dione derivatives<br>[A <sub>13</sub> -A <sub>18</sub> ]                  | 57  |  |
| 3.5                                   | Synthesis of bisimine derivatives [B <sub>1</sub> -B <sub>5</sub> ]                                                 | 59  |  |
| 3.6                                   | Synthesis of bis -1,3-oxazepine-4,7-dione derivatives<br>[B <sub>6</sub> -B <sub>10</sub> ]                         | 61  |  |
| 3.7                                   | Synthesis of bis-1,3-oxazepine-4,7-dione derivatives [B <sub>10</sub> -B <sub>15</sub> ]                            | 63  |  |
| 3.8                                   | Antibacterial activity                                                                                              | 119 |  |
| 3.8.1                                 | Antibacterial tests                                                                                                 | 119 |  |
|                                       | Conclusions                                                                                                         | 127 |  |
|                                       | Prospective studies                                                                                                 | 128 |  |
|                                       | References                                                                                                          | 129 |  |
|                                       | الخلاصة                                                                                                             |     |  |

# List of tables

| No. | Subject                                                                                                              | Pages   |
|-----|----------------------------------------------------------------------------------------------------------------------|---------|
| 2.1 | Chemicals and their manufactures                                                                                     | 27      |
| 2.2 | The physical properties of compounds [A1-A6]                                                                         | 32-33   |
| 2.3 | The physical properties of compounds [A7-A12]                                                                        | 35-36   |
| 2.4 | The physical properties of compounds [A <sub>13</sub> -A <sub>18</sub> ]                                             | 38-39   |
| 2.5 | (C.H.N.) analysis data of 1,3-oxazepine compounds                                                                    | 40      |
|     | [A <sub>7</sub> -A <sub>18</sub> ]                                                                                   |         |
| 2.6 | The physical properties of compounds [B <sub>1</sub> -B <sub>5</sub> ]                                               | 42      |
| 2.7 | The physical properties of compounds [B <sub>6</sub> -B <sub>10</sub> ]                                              | 44      |
| 2.8 | The physical properties of compounds [B <sub>11</sub> -B <sub>15</sub> ]                                             | 46      |
| 2.9 | C.H.Nanalysis data of 1,3-oxazepine compounds [B <sub>6</sub> –B <sub>15</sub> ]                                     | 47      |
| 3.1 | FT-IR data of the synthesizedbis - azoimine derivatives                                                              | 52-53   |
| 3.2 | FT-IR data of the synthesizedbisazobis -1,3-oxazepine-4,7-                                                           | 56      |
|     | dione derivatives [A <sub>7</sub> -A <sub>12</sub> ]                                                                 |         |
| 3.3 | FT-IR data of the synthesized bisazobis -1,3-oxazepine-<br>4.7-dione derivatives [A <sub>13</sub> -A <sub>18</sub> ] | 58      |
| 3.4 | FT-IR data of the synthesized bisimine derivatives [B <sub>1</sub> -B <sub>5</sub> ]                                 | 60      |
| 3.5 | FT-IR data of the synthesized bis -1,3-oxazepine - 4,7-<br>dione derivatives [B <sub>6</sub> - B <sub>10</sub> ]     | 62      |
| • - | FT-IR data of the synthesized bis -1.3-oxazenine - 4.7-                                                              | 64      |
| 3.6 | dione derivatives $[B_{11} - B_{15}]$                                                                                | νT      |
| 3.7 | The antibacterial activities of the synthesized bis -1,3-                                                            | 120-121 |
|     | oxazepine compounds [A8-A20 and B6-B15]                                                                              |         |

# List of figures

| No.  | Subject                                       | Pages |
|------|-----------------------------------------------|-------|
| 3.1  | FT-IR spectrum of o-tolidene                  | 73    |
| 3.2  | FT-IR spectrum of compound [A]                | 74    |
| 3.3  | FT-IR spectrumof compound [A1]                | 75    |
| 3.4  | FT-IR spectrum of compound [A <sub>2</sub> ]  | 76    |
| 3.5  | FT-IR spectrum of compound [A <sub>3</sub> ]  | 77    |
| 3.6  | FT-IR spectrum of compound [A <sub>4</sub> ]  | 78    |
| 3.7  | FT-IR spectrum of compound [A <sub>5</sub> ]  | 79    |
| 3.8  | FT-IR spectrum of compound [A <sub>6</sub> ]  | 80    |
| 3.9  | FT-IR spectrum of compound [A <sub>7</sub> ]  | 81    |
| 3.10 | FT-IR spectrum of compound [A <sub>8</sub> ]  | 82    |
| 3.11 | FT-IR spectrum of compound [A <sub>9</sub> ]  | 83    |
| 3.12 | FT-IR spectrum of compound [A <sub>10</sub> ] | 84    |
| 3.13 | FT-IR spectrum of compound [A <sub>11</sub> ] | 85    |
| 3.14 | FT-IR spectrum of compound [A <sub>12</sub> ] | 86    |
| 3.15 | FT-IR spectrum of compound [A <sub>13</sub> ] | 87    |
| 3.16 | FT-IR spectrum of compound [A <sub>14</sub> ] | 88    |
| 3.17 | FT-IR spectrum of compound [A <sub>15</sub> ] | 89    |
| 3.18 | FT-IR spectrum of compound [A <sub>16</sub> ] | 90    |

| 3.19 | FT-IR spectrum of compound [A <sub>17</sub> ]            | 91  |
|------|----------------------------------------------------------|-----|
| 3.20 | FT-IR spectrum of compound [A <sub>18</sub> ]            | 92  |
| 3.21 | FT-IR spectrum of compound [B <sub>1</sub> ]             | 93  |
| 3.22 | FT-IR spectrum of compound [B <sub>2</sub> ]             | 94  |
| 3.23 | FT-IR spectrum of compound [B <sub>3</sub> ]             | 95  |
| 3.24 | FT-IR spectrum of compound [B4]                          | 96  |
| 3.25 | FT-IR spectrum of compound [B <sub>5</sub> ]             | 97  |
| 3.26 | FT-IR spectrum of compound [B <sub>6</sub> ]             | 98  |
| 3.27 | FT-IR spectrum of compound [B7]                          | 99  |
| 3.28 | FT-IR spectrum of compound [B <sub>8</sub> ]             | 100 |
| 3.29 | FT-IR spectrum of compound [B9]                          | 101 |
| 3.30 | FT-IR spectrum of compound [B <sub>10</sub> ]            | 102 |
| 3.31 | FT-IR spectrum of compound [B <sub>11</sub> ]            | 103 |
| 3.32 | FT-IR spectrum of compound [B <sub>12</sub> ]            | 104 |
| 3.33 | FT-IR spectrum of compound [B <sub>13</sub> ]            | 105 |
| 3.34 | FT-IR spectrum of compound [B <sub>14</sub> ]            | 106 |
| 3.35 | FT-IR spectrum of compound [B <sub>15</sub> ]            | 107 |
| 3.36 | <sup>1</sup> H NMR spectrum of compound[A <sub>7</sub> ] | 108 |
| 3.37 | <sup>1</sup> H NMR spectrum of compound[A <sub>8</sub> ] | 108 |
| 3.38 | <sup>1</sup> H NMR spectrum of compound[A <sub>9</sub> ] | 109 |

| 3.39 | <sup>1</sup> H NMR spectrum of compound[A <sub>10</sub> ]                                                                                                                                                                                                                                                  | 109 |
|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| 3.40 | <sup>1</sup> H NMR spectrum of compound[A <sub>11</sub> ]                                                                                                                                                                                                                                                  | 110 |
| 3.41 | <sup>1</sup> H NMR spectrum of compound[A <sub>13</sub> ]                                                                                                                                                                                                                                                  | 110 |
| 3.42 | <sup>1</sup> H NMR spectrum of compound[A <sub>14</sub> ]                                                                                                                                                                                                                                                  | 111 |
| 3.43 | <sup>1</sup> H NMR spectrum of compound[A <sub>15</sub> ]                                                                                                                                                                                                                                                  | 111 |
| 3.44 | <sup>1</sup> H NMR spectrum of compound[A <sub>16</sub> ]                                                                                                                                                                                                                                                  | 112 |
| 3.45 | <sup>1</sup> H NMR spectrum of compound[A <sub>17</sub> ]                                                                                                                                                                                                                                                  | 112 |
| 3.46 | <sup>1</sup> H NMR spectrum of compound[B <sub>7</sub> ]                                                                                                                                                                                                                                                   | 113 |
| 3.47 | <sup>1</sup> H NMR spectrum of compound[B <sub>8</sub> ]                                                                                                                                                                                                                                                   | 113 |
| 3.48 | <sup>1</sup> H NMR spectrum of compound[B <sub>11</sub> ]                                                                                                                                                                                                                                                  | 114 |
| 3.49 | <sup>1</sup> H NMR spectrum of compound[B <sub>12</sub> ]                                                                                                                                                                                                                                                  | 114 |
| 3.50 | <sup>1</sup> H NMR spectrum of compound[B <sub>13</sub> ]                                                                                                                                                                                                                                                  | 115 |
| 3.51 | <sup>1</sup> H NMR spectrum of compound [B <sub>15</sub> ]                                                                                                                                                                                                                                                 | 115 |
| 3.52 | Antibacterial activity of the synthesized compounds<br>[A <sub>7</sub> ,A <sub>8</sub> ,A <sub>9</sub> ,A <sub>10</sub> ,A <sub>11</sub> ,A <sub>12</sub> ,A <sub>13</sub> ,A <sub>14</sub> ,A <sub>15</sub> ,A <sub>16</sub> ,A <sub>17</sub> ,A <sub>18</sub> ] against<br><i>Staphylococcus aureous</i> | 120 |
| 3.53 | Antibacterial activity of the synthesized compounds<br>[B <sub>6</sub> ,B <sub>7</sub> ,B <sub>8</sub> ,B <sub>9</sub> ,B <sub>10</sub> ,B <sub>11</sub> ,B <sub>12</sub> ,B <sub>13</sub> ,B <sub>14</sub> ,B <sub>15</sub> ] against<br><i>Staphylococcus aureous</i>                                    | 121 |
| 3.54 | Antibacterial activity of the synthesized compounds<br>[A <sub>7</sub> ,A <sub>8</sub> ,A <sub>10</sub> , ,A <sub>11</sub> ,A <sub>12</sub> ,A <sub>13</sub> ,A <sub>15</sub> , ,A <sub>16</sub> ,A <sub>17</sub> ,A <sub>18</sub> ,] against<br><i>E.coli</i>                                             | 122 |
| 3.55 | Antibacterial activity of the synthesized compounds<br>[B <sub>6</sub> ,B <sub>7</sub> ,B <sub>8</sub> ,B <sub>9</sub> ,B <sub>10</sub> ,B <sub>11</sub> ,B <sub>12</sub> ,B <sub>13</sub> ,B <sub>14</sub> ,B <sub>15</sub> ,A <sub>9</sub> ,A <sub>14</sub> ] against<br><i>E.coli</i>                   | 123 |



### 1.1. Azo compounds

Azo compounds are characterized by the presence of azo group (-N=N-) which links two sp<sup>2</sup> hybridized carbon atoms<sup>(1)</sup>. Often, these carbons are part of an extended delocalized electron system involving the aromatic rings, called a chromophore<sup>(2)</sup>. Most azo compounds contain only one azo group, but some contain two, three or more azo groups<sup>(3)</sup>.

Aliphatic azo compounds ( $R_1$ -N=N- $R_2$ ) ( $R_1$  and /or  $R_2$  = alkyl groups) are rather unstable . At an elevated temperature or by irradiating two carbon nitrogen (R-N) bonds are cleaved simultaneously with the loss of nitrogen gas to generate carbon-centered radicals . owing to this process some aliphatic azo compounds are utilized as radical initiators<sup>(4)</sup>.

Electrochemical studies show that the type of the substituted groups on the aromatic ring play an important role on the transformation of the potential of these compounds. However, an electron with drawing groups, such as (NO<sub>2</sub>), have the ability to distribute negative charge to azo compound, by the effect of resonance, forming more stable complexes. Nevertheless, the position of these substitutions on the aromatic ring has also effect on the stability of these complexes<sup>(5)</sup>.

### **1.2.** Synthesis of azo compounds

In general, the preparation of an azo compound requires two organic compounds a diazonium salt and a coupling component<sup>(6)</sup>. This method was well- known as azo coupling as indicated in scheme (1-1).





Aryldiazonium salts are prepared by treating an acidic solution of aniline and their derivitives with presence of sodium nitrite and hydrochloric acid. Scheme (1-2).



Scheme (1-2) : Formation of aryldiazonium salt

Diazonium salts are unstable and can be explosive when dry<sup>(7)</sup>. Therefore, they are always prepared as needed under acidic condition with good stirring, kept at near 0°C, otherwise they react with water to produce a phenol, and must be used immediately in the coupling reaction.

Adegoke et al.<sup>(8)</sup>prepared the new azo compound [2]. The procedure involves coupling of diazotized nitroimidazol [1] with p-N,N-dimethylaminobenzaldehyde to form a greenish-yellow solution. Scheme



Scheme (1-3) : Formation of azo compond [2] via coupling reaction

### **1.3.** Isomerism in azo compounds

As with any double bond, the planar  $(-N=N^-)$  bond usually exists in two geometrical isomers *cis* and *trans*. The *trans* isomer is considered to be the more preferable one<sup>(9)</sup>.Scheme (1-4).



Scheme (1-4): Structures of trans and cis-azobenzene

The change from *trans* to *cis* will be effected by exposure to UVradiation . This can lead to photochromism , a light induced reversible color change in some dyes .This effect was considered a nuisance and has largely been eliminated by careful development of more stable dyes. But photochromic dyes are beginning to make a comeback in technology like sunglasses and sunroofs in cars<sup>(10,11)</sup>.

The aromatic azo compounds were identified to be more stable than the aliphatic one . This is in fact because of the presence of a tautomeric equilibrium form. This involves the removal of a hydrogen from one part of the molecule , and the addition of a hydrogen to a different part of the molecule , this is common when there is an (-OH) group *ortho* or *para* to the azo group<sup>(12)</sup>as shown in .Scheme (1-5).



Scheme (1-5) : Tautomerism in azo compound [5]

Tautomeric forms can be identified through their characteristic spectra . Ketohydrazones are normally bathochromic compared to their counterpart hydroxyazo forms. Ketohydrazones also have higher molar extinction coefficients. However , not all azo compounds show tautomerism and some tautomeric forms are more stable than others<sup>(13)</sup>.

Many authors<sup>(13-16)</sup> have investigated the intramolecular hydrogen bonding in some azo compounds. They related the low dissociation constant to the electrostatic effects of the ring substituent on the electronegativity of the azo nitrogen acting as a proton acceptor. The deprotonation of the *ortho*- hydroxy group usually proceeds more slowly when the hydrogen bond becomes stronger<sup>(17)</sup>.Scheme (1-6).



Scheme (1-6) : Tautomerism in azo compound [7]

### **1.4. Importance of azo compounds**

Azo compounds constitute one of the largest classes of industrially synthesized organic compounds. Aliphatic azo compound , like azobisisobutyronitrile ( AIBN ), can be as radical initiators in polymerization of alkenes to make plastics<sup>(18)</sup>.

Aromatic azo compounds are used as acid-base indicators such as methyl red [10], methyl orange [11] and congo red [12] <sup>(19)</sup>as shown in scheme (1-7).



Scheme (1-7) : Using of azo compounds as indicators

Azo compounds are important in the synthesis of drugs, cosmetics and azo dyes <sup>(20)</sup>. Azo dyes form ( 60-70 %) of all synthetic dyes used as commercial colorants . Azo dyes have several advantages over other commercial dyes including their wide color range, good color fastness and they can be synthesized cheaply because the starting materials are readily available and inexpensive compounds. Azo compounds show a variety of interesting biological activities including antibacterial <sup>(21)</sup>, antifungal<sup>(22)</sup> and anticancer<sup>(23)</sup>.

Some azo dyes were published as antimicrobial agents<sup>(24)</sup>, for example ; prontosil [13], salicylazosulfopyriden [14] and 6-(4-hydroxy phenyazo) uracil [15] in 1998, Bradshow et al.<sup>(25)</sup>showed that 2-(3- substituted 4-amino phenyl)benzothiazole derivatives [16] were a novel class of potent and selective antitumour agents which exhibit nanomolar inhibitory activity against a range of human breast, ovarian, colon and renal cell lines in vitro as shown in scheme (1-8).





Mkpenie et al.<sup>(26)</sup>prepared 1-(4-methylphenylazo)-2-naphthol [17] and studied the inhibition effect on the biological activities of some bacteria like *Escherichia.coli* and *Staphylococcus.aureus*.



compound [17]

Mossalamy<sup>(27)</sup> prepared sulfonamide azo dyes [18] by the reaction sulfonamide with derivatives of phenol and were used as ligands.



compound [18]

### **1.5. Schiff bases**

Schiff bases are compounds which contain an azomethine group  $\begin{pmatrix} \ddots & I \\ -N = C - \end{pmatrix}$ . They are named after Schiff who prepared a number of these bases via condensation of aliphatic and aromatic aldehydes and ketones

with primary aromatic amines, primary aliphatic amines and amino acids<sup>(28)</sup>.

The general formula of these Schiff bases is and their nomenclature depends on the nature of the groups  $R - \ddot{N} = C < {R_1 \atop R_2} R$ ,  $R_1$ ,  $R_2$  (<sup>29)</sup>. The compound C<sub>6</sub>H<sub>5</sub>- $\ddot{N}$ =CHC<sub>6</sub>H<sub>5</sub> [19], for example, is named as*N*-benzyli- deneaniline (an old name), or *N*-benzylidenebenzeneamine (systematic name) and it is anaromatic Schiff base , while the compound (C<sub>4</sub>H<sub>9</sub>- $\ddot{N}$ =CH-C<sub>2</sub>H<sub>5</sub>) is named as *N*-propylidenebutylamine, and it is an aliphatic Schiff base. There are other names for starting material such as azomethine Schiff base, anil, imine, ketimine, benzylideneaniline, benzalaniline (or benzaniline), benzalanil (or benzanil), and as the Schiff base of benzaldehyde and aniline<sup>(30)</sup>. Aromatic Schiff bases are considered as a chromophores due to conjugation of the electron pair on the nitrogen atom with the benzene ring of aniline and benzaldehyde <sup>(31)</sup>.



compound [19]

### 1.6. Synthesis of Schiff bases

Ammonia or primary amines add to the carbonyl group of aldehydes or Ketones to give hemiaminals (also called "aldehyde ammonias ") which decompose to the imines or Schiff bases <sup>(32,33)</sup> as shown in scheme (1-9).



Scheme (1-9) : Formation of Schiff bases through condensation of aldehydes or ketones with ammonia or primary amines

The reaction may be catalyzed by protonating the carbonyl group<sup>(34)</sup>the reaction is believed to follow the mechanism shown in scheme (1-10).



nmine formatioiMechanism of ):01-Scheme (1

In general, the resulting imine is unstable  $^{(32)}$ . The stability of the final product depends on the nature of the starting aldehyde or ketone and the amine . It can be concluded that the stabilized Schiff bases may be prepared from the following types of compounds as shown in scheme  $(1-11)^{(35)}$ .



Scheme (1-11) : Effect of the structure on the stability of Schiff bases

Verma et al. <sup>(36)</sup> synthesized Schiff bases of *N*-methyl and *N*-acetyl isatin derivatives [20] as shown in scheme (1-12).



Scheme (1-12): Synthesis of N- methyl and N- acetyl isatin derivatives

Compounds containing each azo and imine groups are called azoimines or azo Schiff bases which are prepared starting from azoaldehydes and primary amines through catalytic condensation reaction. Basu et al. <sup>(37)</sup>prepared new azo Schiff base derivative [22] via acid-catalysed condensation reaction between azoaldehydes derivative



Scheme (1-13) : Structure of azo Schiff base derivative [22]

Zarei et al.<sup>(38)</sup> prepared azo Schiff bases derivatives [23] with free solvent in green method and high yield as shown in scheme (1-14).



Scheme(1-14): Synthesis of azo Schiff base derivatives[23]

### 1.7. Reactions of Schiff bases

### 1.7.1. Addition reactions

Schiff bases undergo addition reactions to the azomethine group, the reagents are added to the polarized double bond  $\left(\geq \overset{\delta^+}{=} \overset{\delta^-}{=}\right)$  so,nucleo-philic reagents attack the carbon atom of the azomethine linkage.

### 1.7.1.1. Addition of alkyl halides

The alkylation of Schiff bases with alkyl halides results in a quaternary iminium salts [24], which are converted to secondary amines [25] uponhydrolysis<sup>(39)</sup>. The alkylation is used to synthesis of secondary amines as shown in scheme (1-15).

$$\begin{array}{c}
\overset{\cdot}{\mathsf{C}_{6}\mathsf{H}_{5}} \xrightarrow{\mathsf{C}_{6}} \overset{\bullet}{\mathsf{H}_{5}} \xrightarrow{\mathsf{C}_{6}} \overset{\bullet}{\mathsf{H}_{5}} \xrightarrow{\mathsf{C}_{6}} \overset{\bullet}{\mathsf{H}_{5}} \xrightarrow{\mathsf{C}_{6}} \overset{\bullet}{\mathsf{H}_{5}} \overset{\bullet}{\mathsf{H}_{5}} \xrightarrow{\mathsf{C}_{6}} \overset{\bullet}{\mathsf{H}_{5}} \overset{\bullet}{$$

Scheme (1-15) : Alkylation of imines to the secondaryamines [25] through reaction with alkyl halides

### 1.7.1.2. Addition of carboxylic acid chlorides

It is found that acidchlorides such as acetyl chloride and *p*-anisoyl chloride are added to Schiff bases to give the addition products  $[26]^{(40)}$  and  $[27]^{(41)}$  respectively as shown in scheme (1-16).



Scheme (1-16) : Addition of acetyl chloride and *p*-anisoylchloride to azomethine group to give the addition products [26] and [27] respectively

### 1.7.1.3. Addition of maleic and succinic anhydrides

Anils react with maleic anhydride in the presence of water to form maleanilic acid [28] and aldehydes<sup>(42)</sup>. When an anil is heated with maleic anhydride in toluene, maleanilic acid [28] is also obtained<sup>(43)</sup>. Whereas the formation of a condensation product has been reported when the mixture is heated without using the solvent. Crotonaldehydeanil and cinnamaldehydeanil react with maleic anhydride in xylene to form an addition products<sup>(44)</sup>.Scheme (1-17).



Scheme (1-17) : Fomation of maleanilic acid [28] from anils

The condensation of benzylidenemethylamine [29] with succinic anhydride yields *trans*- and *cis*- 1-methyl4-carboxy-5-phenyl-2- pyrrolidin-one [30] and [31] respectively<sup>(45)</sup>. Scheme (1-18).



Scheme (1-18) : Addition of succinic anhydride to imine [29]

### 1.7.1.4. Addition of Grignard reagents

Grignard reagents react with azomethine compounds to form addition products which on hydrolysis result in secondary amines [32]. The reaction is usually applied to the Schiff bases which are prepared from aryl aldehydes<sup>(46)</sup>as shown in scheme (1-19).



Scheme (1-19) : Addition of Grignard reagents to imines

### 1.7.1.5. Addition of hydrogen

Schiff bases can be hydrogenated in the presence of catalyst to give the corresponding secondary amines<sup>(47)</sup> [33]. Scheme (1-20).

$$CH_3 - N = CH - C_6H_5 \xrightarrow{H_2} CH_3 - NHCH_2C_6H_5$$
  
Ni [33]

Scheme (1-20) : Hydrogenation of imines

### 1.7.2. Cycloaddition reactions

For several years, the Diels- Alder reaction was the only widely useful example of the so-called cycloaddition reactions<sup>(48)</sup>. The extensive generalization by Huisgen and his school of the concept of 1,3-dipolar cycloadditions, first recognized by Schmidt, has opened new avenues for investigations<sup>(49)</sup>. The dimerazation of olefins, as well as the addition of carbenes and nitrenes to unsaturated centers has extended the series to include three-, four-, five- and six-membered ring systems. Huisgen et al.<sup>(48)</sup>. <sup>(49)</sup> have reviewed cycloaddition reactions of alkenes, and here we will deal with the various cycloaddition of the azomethine bond (C = N - ).

### 1.7.2.1. Formation of three-membered rings

Dichlorocarbene added to *N*-benzylideneaniline [19] to give the corresponding dichloroaziridine<sup>(50)</sup> [34]. Scheme (1-21).



Scheme (1-21) : Synthesis of aziridine ring via cycloaddition of dichlorocarbene to azomethine bond

Deyrup and Grunewald<sup>(51)</sup>have shown that the reaction of diphenylmethyleneaniline [35] with chloroform and potassium t-butoxide gave 3,3- dichloro-1,2,2-triphenylaziridine [36] as shown in scheme (1-22).



Scheme (1-22) : Synthesis of aziridine ring via cycloaddition of cloroform toazomethine bond

### 1.7.2.2. Formation of four- membered rings

Staudinger<sup>(52)</sup>reported the formation of 1,3,3,4-tetraphenyl-2azetidinone [38] via [2+2] cycloaddition of diphenylketene [37] with *N*benzylideneaniline [19]. Scheme (1-23).





### 1.7.2.3. Formation of five-membered rings

Buckley<sup>(53)</sup> reported the reaction of diazomethane with *p*-nitro-*N*-(*p*-nitrobenzylidene) aniline [39] and assigned the 1,2,3-triazoline structure [40] via 1,3-dipolar cycloaddition. Scheme (1-24).



Scheme (1-24) : Formation of 1,2,3-triazoline ring via1,3-dipolar cycloaddition of diazomethane to imine group

### 1.7.2.4. Formation of six-membered rings

Alder<sup>(54)</sup> mentions that the reaction of imino form of dimethyl anilinomaleate [41] with *c* is dienes gives tetrahydropyridine [42]. The influence of an electron-withdrawing groups attached to imine bond is the key factor to do the reaction as shown in scheme (1-25).



Scheme (1-25) : Formation of tetrahydropyridine derivative [42] via [4+2] cycloaddition of imino group to *c*is 2,3- dimethyl-1,3-butadiene

### **1.8. Schiff bases uses**

Schiff bases are starting materials for the preparation of a large number of heterocyclic compounds<sup>(55)</sup> and their complexes<sup>(56)</sup>. They are also used to prepare super - conducting polymers <sup>(57)</sup>.

Schiff bases are reported to show a variety of interesting biological actions including antibacterial<sup>(58)</sup>,antifungal<sup>(59)</sup>,antivirus(MHV)<sup>(60)</sup>,

anticonvulsant<sup>(36)</sup>, anticancerand herbicidal activities<sup>(38)</sup>, it is also known that the presence of an azo moiety in different types of Schiff bases can
lead them to exhibit pesticidal activities<sup>(61)</sup>. Both Schiff bases and azo compounds are important structures in the medicinal and pharmaceutical fields <sup>(60)</sup>. And it has been suggested that the azomethine linkage might be responsible for biological activities displayed by Schiff bases <sup>(62)</sup>. In the light of the interesting variety of biological activities seen in compounds containing azo and azomethine linkage. So many methods were reported for the synthesis of Schiff bases .

#### **1.9. Pericyclic reactions**

Pericyclic reaction represents an important class of concerted (single step) processes involving  $\pi$ -systems, a concerted rearrangement of the electrons takes place that causes  $\sigma$  and  $\pi$ -bonds are broken and formed simultaneously. While the classical organic reactions involve several steps or rearrangement with side reactions and relatively low yield, the pericyclic reaction is one step-process and takes place through a single transition state (T.S) with relatively high yield and no side reactions<sup>(63)</sup>.Concerted reactions include three major classes :

#### **1.9.1. Electrocyclic reactions**

Electrocyclic reactions is a pericyclic process that involve the cyclization of a conjugated polyene. One  $\pi$ -bond is broken, the other  $\pi$ -bond is changed position then a new  $\sigma$ -bond is formed and a cyclic compound is resulted. For example *c* is 1,3-butadiene [43] can be converted to acyclobutene [44]<sup>(64)</sup>under heating as shown in scheme (1-26)



Scheme (1-26) : Conversion of cis1,3- butadiene to cyclobutene under heating

## **1.9.2.** Cycloaddition reactions

There is number of reactions of alkenes and polyene in which two molecules form a cyclic product [45]. These reactions are called cycloadditon reactions. The Diels-Alder reaction is one type of this reaction<sup>(65)</sup>.Scheme (1-27).



Scheme (1- 27 ) : Formation of six- membered ring via [2+4] cycloaddtion of alkene and cis 1,3-butadiene

#### 1.9.3. Sigmatropic rearrangements

Sigmatropic rearrangements are unimolecular processes, like electrocyclic reactions, and involve the movement of a  $\sigma$ -bond with the simultaneous rearrangement of the  $\pi$ -system<sup>(66)</sup>. Scheme (1-28)



Scheme (1-28) : Sigmatropic rearrangement reaction

The Cope rearrangement is important example on sigmatropic rearrangement<sup>(67)</sup>.Scheme (1-29).



Scheme (1-29) : Cope rearrangement reaction

#### 1.10. Synthesis of 1,3- and 1,4-oxazepines

Oxazepine is non-homologous seven-membered ring that contains two hetero atom (oxygen and nitrogen) as shown in Scheme (1-30).



Scheme (1-30) : Structures of 1,3- and 1,4- oxazepine rings

For a long time, the synthesis of 1,3- and 1,4-oxazepine rings were based on two limited classical types of reaction, the first reaction is called (Valencebond isomerization) which is carried out via irradiation of polyaryl pyridiine *N*oxides [52]. This irradiation results in ring expansion to 1,3-oxazepine derivatives<sup>(68)</sup> [53] as shown in scheme (1-31).



Scheme (1-31) : Mechanism of pyridine ring expansion to seven-membered1,3oxazepine ring

The second reaction is called (Enamine condensation) which is carried out via irradiation of enamine derivative [54] to produced 2,3,6-trihydro-5-methoxy carbonyl-2,3,4-triphenyl-1,4-oxazepin-7-one [55] and [56] as its hemiacetal<sup>(69)</sup>.Scheme (1-32).



Scheme (1-32) : Formation of 1,4- oxazepines [ 55] and [56] via irradiation of enamines derivative [54]

The<sup>(69)</sup> mechanism of this reaction is shown in scheme (1-33).



Scheme (1-33) : Mechanism of irradiation of enaminederivative [54] to produce 1,4oxazepine ring

Recently, pericyclic reactions are used in synthesise of 1,3-oxazepine ring<sup>(70,71)</sup>.Jawad<sup>(72)</sup>prepared new 1,3-oxazepine derivative [58] starting from L-Ascorbic acid [57] .Scheme (1-34) .



Scheme (1-34) : Formation of 1,3-oxazepine derivatives [58] through cycloaddition reaction of imino ascorbic acid to maleic anhydride

Hameed<sup>(73)</sup>synthesis of four new 1,3,4-oxadiazole derivatives containing 1,3-oxazepine moiety [60] by microwave assisted organic synthesis method through the addition reaction of 2-[4-(arylidene) phenyl-1,3,4-oxadiazole-5-thiol] [59] with maleic anhydride under variable microwave power (180,510) watt.Scheme (1-35).



#### Scheme (1-35) : Synthesis of 1,3-oxazepines [60] through addition of maleic anhydride to imines [59] under variable microwave power

Yousif<sup>(74)</sup>synthesis of several Schiff bases [62] by condensation of 6- methoxy - 2- amino benzothiazole [61] with some aldehydes and ketones (2- hydroxyl benzaldehyde, 4- hydroxyl benzaldehyde, 4- N,N –dimethy amino acetophenone, benzophenone) to obtain Schiff bases which were found to react with phthalic anhydride to give1,3- oxazepine derivatives [63].Scheme (1-36).



Scheme (1-36) : Formation of 1,3-oxazepine derivatives [63] containing benzothiazole moiety

Mahrath et al.<sup>(75)</sup> synthesized new bis- 1,3 oxazepine 4,7- dione derivatives [65] via [2+5] cycloaddition of phthalic anhydride to imines [64]. Scheme (1-37).



Scheme (1-37) : Synthesis of bis - 1,3- oxazepine derivatives [65] via [2+5] cycloaddition of phthalic anhydride to bis-imines [64]

Abood<sup>(76)</sup> synthesized new bis-1,3–oxazepine-4,7- dione derivatives [69] and [70] containing two azo groups and 1,3,4-thiadiazole or benzothiazole moieties as shown in scheme (1-38).



Scheme (1-38) : Synthesis of bis-1,3-oxazepine derivatives containing two azo groups and 1,3,4-thiadiazole or benzothiazole moieties [67] and [68]

Samet et al.<sup>(77)</sup>synthesized of benzo [f] naphthol [b][1,4] oxazepines [72] from TNT [71] as shown in scheme (1-39).



Scheme (1-39) : Synthesis of benzo [f] naphthol [b] [1,4] oxazepines [72] from TNT [71]

Jain et al.<sup>(78)</sup> synthesized a series of new substituted N-11-(40-N-aryl carboxamido / N-(aryl)-a-phenyl-acetamido-piperazinyl) -dibenz [b,f] [1,4]-oxazepine derivatives [73] and [74] were designed on a revised structural model the present study demonstrates significant antipsychotic activity as shown in scheme (1-40).



Scheme (1-40) : Synthesis of dibenz[b,f][1,4]-oxazepine derivatives [73] and [74]

#### 1.11. Importance of oxazepine

Oxazepine and their derivatives have some important biological pharmacological activities<sup>(79)</sup> such as enzyme inhibitors<sup>(80)</sup>, analgesic<sup>(81)</sup>, antidepressant<sup>(82)</sup>and psychoactive drug<sup>(83)</sup>. Amoxapine [75] is a group of drugs called tricyclic antidepressants. It is used to treat symptoms of depression, anxiety and agitation <sup>(84)</sup>.



compound [75]

Dibenz [b,f]-1,4-oxazepine [76] is used in chemical weapons as tear gas. Tear gas is the common name for a low concentration substance, cause pain in eyes, flow of tears and difficulty in keeping eyes open. It is used mainly in military exercises and in riot control<sup>(85)</sup>.



compound [76]

Guan etal.<sup>(86)</sup> prepared new1,3- oxazepine- 4,7- dione derivatives [77] and study their liguid crystalline properties.



compound [77]

Aiello et al.<sup>(87)</sup>prepared2- Chloro-11(4-methyl-piperazin-1-yl) dibenzo[b,f] [1,4]oxazepine [78] and used it as anti-psychoactive.



compound [78]

Serrano et al.<sup>(88)</sup> evaluated the biological activity of 1,4-oxazepine derivative [79], medically- known as Sordarin which showed antifungal activity against three types of fungi *are candida albicans,candida glabrata and cryptococcus neoformas*.



compound [79]

Xin-Hua Liu et al.<sup>(89)</sup> synthesized eight novel 4,5-tetrahydropyrazolo [1,5-d][1,4] oxazepine derivatives [80] to be screened for anticancer activity.



compound [80]

Xian-Qing Denget al.<sup>(90)</sup>synthesized novel series of 10-alkoxy-5, 6-dihydro-triazolo[4,3-d] benzo[f][1,4] oxazepine derivatives [81] were screened for their anticonvulsant activities by the maximal electroshock (MES) test.



compound [81]

Seennaiah et al.<sup>(91)</sup>synthesized a series of [1,2,3-triazolo [5,1-c][1,4] benzoxazepine derivatives [82] as antibacterial.



compound [82]

## Aim of the study

This work aims to synthesis the preliminary evaluation of antibactrial activity of two new series of bis-1,3-oxazepine-4,7-dione derivatives, the first series contains azo groups while the second does not.



## 2. Experimental part

## 2.1. Materials

Table (2-1) shows the utilized chemicals in the experimental course of the thesis.

| Table (2-1) : Chemicals and their manufacture | es |
|-----------------------------------------------|----|
|-----------------------------------------------|----|

| Chamical                                         | M.Wt. | Purity | Supplied |  |
|--------------------------------------------------|-------|--------|----------|--|
| Chemicai                                         | g/mol | %      | from     |  |
| o-Tolidine                                       | 212   | 99     | Merck    |  |
| Sodium nitrite                                   | 69    | 99     | BDH      |  |
| Hydrochloric acid (Conc.)                        | 36.5  | 99     | Merck    |  |
| 4- <i>N</i> , <i>N</i> Dimethylaminobenzaldehyde | 149   | 99     | Merck    |  |
| Ethanol( absolute)                               | 46    | 99.9   | BDH      |  |
| Sodium hydroxide                                 | 40    | 99     | BDH      |  |
| 4- Clorobenzaldehyde                             | 140   | 99     | Merck    |  |
| 4-Methoxyaniline                                 | 123   | 99     | Fluka    |  |
| 2-Hydroxybenzaldehyde                            | 122   | 99     | BDH      |  |
| Glacial acetic acid                              | 60    | 99.9   | GCC      |  |
| Maleic anhydride                                 | 98    | 99     | BDH      |  |
| Phthalic anhydride                               | 148   | 99     | BDH      |  |
| Benzene                                          | 78    | 99.9   | GCC      |  |
| Methanol                                         | 32    | 95     | BDH      |  |
| benzaldehyde                                     | 106   | 99     | Merk     |  |
| Ethyl acetate                                    | 88    | 99     | BDH      |  |

| Dimethyl sulfoxide          | 78  | 99   | BDH               |
|-----------------------------|-----|------|-------------------|
| Diethyl ether               | 72  | 99   | BDH               |
| Chloroform                  | 118 | 99   | BDH               |
| 2,5- Dimethoxybenzaldehyde  | 166 | 99   | Merk              |
| 2,4- Dimethylaniline        | 121 | 99   | Merk              |
| 2,4- Dinitrophenylhydrazine | 198 | 99   | Merk              |
| Aniline                     | 93  | 99   | BDH               |
| Phenylhydrazine             | 108 | 99   | BDH               |
| Cyclohexyl amine            | 99  | 99   | BDH               |
| 4- Bromoaniline             | 172 | 98   | BDH               |
| <i>n</i> - Hexane           | 86  | 99   | Scharla,<br>Spain |
| Iodine                      | 254 | 99.5 | GCC,<br>Germany   |

#### 2.2. Instrumentations

- 1. Thin layer chromatography (TLC) was performed on aluminum plates and coated with 0.25 mm layer of silica gel  $60 \text{ F}_{254}$ , compounds were detected by iodine vapor.
- 2. Melting points were recorded using status melting point apparatus, UK.
- FT-IR spectra were recorded using Fourier transform infrared SHIMADZU FT-IR-8400S infrared spectrophotometer by KBr disc, University of Kerbala.
- 4. <sup>1</sup>H NMR spectra were recorded on Fourier transform Varian spectrometer, operating at 300 MH<sub>Z</sub> with tetramethylsilane as internal standard and DMSO-d<sub>6</sub> as solvent, measurements were made at Metu Central Laboratory, Orta DoGu Teknik Üniversitesi, Turkey.
- 5. The elemental analyses were recorded using E.A.G.E.R.-100, Carlo Erba, Italy, measurements were made at Metu Central Laboratory, Orta DoGu Teknik Üniversitesi, Turkey.
- 6. Autoclave was used to sterilize agar media, supplied from Prestige Medical-England
- 7. Incubator was used to maintain different temperature required for the growth of organism, supplied from Memert-Germany

#### 2.3. Synthesis methods

#### 2.3.1. Synthesis of 5,5'-((3,3'-dimethyl-[1,1'-biphenyl]-4, 4'-diyl) bis

(diazene-2,1diyl))bis(2-hydroxybenzaldehyde) [A]



Scheme (2-1) : Synthesis of bis-azoaldehyde derivative [A ]

*o*-Toludine (2.12 g ,0.01mol) was dissolved in mixture of concentrated hydrochloric acid (6.4 mL) with distilled water (6.4 mL). The mixture was cooled at 0 °C in ice-water bath. Then a solution of sodium nitrite (1.6 g) dissolved in distilled water (8 mL) was prepared. This solution was added a dropwise to the mixture with stirring. In another beaker asoultin of 2- hydroxybenzaldehyde (2.6 g) dissolved in (20 mL) of (10 % w\v) sodium hydroxide solution was prepared and then coold in ice-water bath to (0-5°C) and stirred vigorously. The cold diazonium chloride was added to the coupling agent in small portions and stirred after each addition, after the addition was completed, the reaction mixture was occasional stirred at 0°C for 1hours. The orange product was precipitated ,filtered, washed well with distilled water and recrystallized from ethanol, yield (61 %), m.p. >300°C and R<sub>f</sub> = 0.72 (chloroform : benzene,1:1).

## 2.3.2. General procedure for Synthesis of bis-azoimine derivatives [A1-A6]



Scheme (2-2) : Synthesis of bis - azoimines [A<sub>1</sub>-A<sub>6</sub>]

Bis-azoaldehyde derivative [A] (0.956g, 0.002 mol) was dissolved in absolute ethanol (20 mL) containing two drops of glacial acetic acid, then equimolar amount (0.004 mol)of primary aromatic amines (cyclohexylamine, phenylhydrazine, 2,4-dimethylaniline, 4-methoxyaniline aniline and 4-bromoaniline) were added. The reaction mixture was refluxed with stirring on a water bath at 70°C for (12-18 h.). TLC (Et<sub>2</sub>O:nhexane, 2:1) showed that the reaction was completed. The mixture was allowed to cool to room temperature and the colored precipitate was filtered, then recrystallized from ethanol. Table (2-2) shows the structures, molecular formulas, molecular weights, melting points, yield% and  $R_f$ values of the synthesized compounds [A] and  $[A_1-A_6]$ .

 Table (2-2) : The physical properties of compounds [A] and [A1-A6]

| Com.           | Structural formula                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Name                                                                                                                                                                              | M.F.                 | M.Wt. | M.p. <sup>0</sup> C | Color          | Yield | $\mathbf{R.T.}$ | $\mathbf{R}_{f}$                                     |
|----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------|-------|---------------------|----------------|-------|-----------------|------------------------------------------------------|
| 10.            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                                                                                                                                                   |                      | g/mor |                     |                | 70    | ( <i>n</i> .)   |                                                      |
| A              | HO N:N N-N-N-N-N-OH                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 5,5'-((3,3'-dimethyl-[1,1'-<br>biphenyl]-4,4'-diyl)bis<br>(diazene-2,1-diyl))bis(2-<br>hydroxybenzaldehyde)                                                                       | $C_{28}H_{20}N_4O_4$ | 478   | >300<br>dec.        | Pale<br>orange | 61    | -               | 0.78<br>(cloroform:benzene)<br>1:1                   |
| $\mathbf{A}_1$ | $HO \longrightarrow H_3C \longrightarrow CH_3$ $HO \longrightarrow HC \approx_N \longrightarrow H$                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 2-((Z)-(cyclohexylimino)<br>methyl)-4-((4'-((3-<br>((cyclohexylimino)methyl)-<br>4- hydroxyphenyl)diazenyl)<br>-3,3'-dimethyl-[1,1'-bi<br>phenyl]-4-yl)diazenyl)<br>phenol        | $C_{40}H_{44}N_6O_2$ | 640   | 150-152             | red            | 91    | 12              | 0.85<br>(Et <sub>2</sub> O: <i>n</i> -hexane)<br>2:1 |
| A <sub>2</sub> | $HO - H_{3}C + H_{3}$ | 4-((4'-((4-hydroxy-3-(( 2-<br>phenylhydrazono) methyl)<br>phenyl) diazenyl)-3,3'-di<br>methyl-[1,1'-biphenyl] -4-<br>yl)diazenyl)-2-((Z)-(2-<br>phenylhydrazono)methyl)<br>phenol | C40H34N8O2           | 658   | 240-242             | red            | 83    | 16              | 0.79<br>(Et <sub>2</sub> O: <i>n</i> -hexane)<br>2:1 |

| $A_3$ | $H_{3}C$<br>HO<br>HO<br>HO<br>HO<br>HO<br>HO<br>HO<br>HO                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 2- (((2,4-dimethylphenyl)<br>imino) methyl)-4-((4-((3-<br>((2)-((24-<br>dimethylphenyl) imino)<br>methyl)-4-hydroxy,<br>phenyl diazenyl)-3,3'-<br>dime thyl-[1,1]-<br>biphenyl]-4-yl)<br>diazenyl)phenol | $C_{44}H_{40}N_6O_2$     | 684 | 248-250 | orange         | 79 | 15 | 0.71<br>(Et <sub>2</sub> O: <i>n</i> -hexane)<br>2:1 |
|-------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------|-----|---------|----------------|----|----|------------------------------------------------------|
| $A_4$ | $H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$ $H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>H | 4-((4'-((4-hydroxy-3-(((4-<br>methoxyphenyl)imino)m<br>ethyl)phenyl)diazenyl)-<br>3,3'-dimethyl-[1,1'-<br>biphenyl] -4-<br>yl)diazenyl)-2-((Z)-((4-<br>methoxyphenyl)imino)<br>methyl)phenol             | $C_{42}H_{36}N_6O_4$     | 688 | 230-232 | orange         | 87 | 13 | 0.85<br>(Et <sub>2</sub> O: <i>n</i> -hexane)<br>2:1 |
| $A_5$ | $HO \longrightarrow N=N \longrightarrow OH$ $HC \sim_N \longrightarrow OH$ $HC \sim_N \longrightarrow OH$                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 4-((4'-((4-hydroxy-3-((Z)-<br>(phenylimino)methyl)phe<br>nyl)diazenyl)-<br>3,3'dimethyl[1,1'-<br>biphenyl]-4-yl) diazenyl) -<br>2-((phenyl imino)methyl)<br>phenol                                       | $C_{40}H_{32}N_6O_2$     | 628 | 170-172 | dark<br>orange | 89 | 16 | 0.67<br>(Et <sub>2</sub> O: <i>n</i> -hexane)<br>2:1 |
| $A_6$ | HO - N = N - OH $HC = N - OH$                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 2-(((4-bromophenyl)<br>imino)methyl)-4-((4'-((3-<br>((Z)-((4-<br>bromophenyl)imino)meth<br>yl)-4-hydroxy<br>phenyl)diazenyl)-3,3'-<br>dimethyl-[1,1'-biphenyl]-<br>4-yl)diazenyl)phenol                  | $C_{40}H_{30}N_6O_2Br_2$ | 786 | 210-212 | brown          | 79 | 18 | 0.65<br>(Et <sub>2</sub> O: <i>n</i> -hexane)<br>2:1 |

## 2.3.3. General procedure for synthesis of bisazobis -1,3-oxazepine-4,7-dione derivatives [A<sub>7</sub>-A<sub>12</sub>]



Scheme (2-3): Synthesis of bisazobis-1,3 oxazepine-4,7-dione derivatives [A7-A12]

A mixture of equimolar amounts of bis-azoimines  $[A_1-A_6]$  (0.0006 mol) and phthalic anhydride (0.1776g, 0.0012mol) in dry benzene (20 mL) was refluxed with stirring on a water bath at 75<sup>o</sup>C for (17-24 h.). TLC (EtOAc : *n*-hexane , 2 : 1) showed that the reaction was completed . Then, the solvent was removed under reduced pressure and the resulting colored solid was washed well with ether and recrystallized from ethanol.

Table (2-3) shows the structures , molecular formulas , molecular weights , melting points, yield% and  $R_f$  values of the synthesized compounds [A<sub>7</sub>-A<sub>12</sub>].

The (C.H.N.) elementary microanalysis data of the synthesized compounds  $[A_7-A_{12}]$  was listed in table (2-5).

| Com.           | Structural formula                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Name                                                                                                                                                                                                                                                                                              | M.F.                                                          | M.Wt. | M.P. <sup>0</sup> C | Color         | Yield | $\mathbf{R.T.}$ | $\mathbf{R}_{f}$                                |
|----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------|-------|---------------------|---------------|-------|-----------------|-------------------------------------------------|
| A <sub>7</sub> | $H_{3}C$ $H$ | 3,3'-(((3,3'-dimethyl-[1,1'-bi<br>phenyl]-4,4'-diyl)bis(diazene-2,1-<br>diyl))bis(2-hydroxy-5,1-<br>phenylene))bis(4-cyclohexyl-3,4-<br>dihydrobenzo[e][1,3] oxazepine-<br>1,5(6H,9H)-dione)                                                                                                      | C <sub>56</sub> H <sub>52</sub> N <sub>6</sub> O <sub>8</sub> | 936   | 222-224             | dark<br>brown | 68    | 17              | 0.69<br>(EtOAc: <i>n</i> -hexane)<br><b>3:1</b> |
| A <sub>8</sub> | $H_{3}C$ $H$ | 3-(5-((4'-((3-(1,5-dioxo-4-<br>(phenylamino)-1,3,4,5,5a,6,9,9a -<br>octahydrobenzo[e][1,3] oxazepine<br>-3-yl)-4-hydroxy phenyl) diazenyl<br>)-3,3'-dimethyl-[1,1'-biphenyl]-4-<br>yl) diazenyl)-2-hydroxyphenyl)-<br>4-(phenylamino)-3,4-dihydro<br>benzo[e] [1,3]oxazepine-1,5<br>(6H,9H)-dione | C <sub>56</sub> H <sub>42</sub> N <sub>8</sub> O <sub>8</sub> | 954   | 232-233             | dark<br>red   | 68    | 24              | 0.74<br>(EtOAc: <i>n</i> -hexane)<br><b>3:1</b> |
| A9             | $HO \longrightarrow H_{3}C \longrightarrow CH_{3}$ $HO \longrightarrow H_{3}C \longrightarrow CH_{3}$ $O = \bigcup_{H_{3}C} H \longrightarrow CH_{3}$ $O = \bigcup_{H_{3}C} H \longrightarrow CH_{3}$ $O = \bigcup_{H_{3}C} H \longrightarrow CH_{3}$                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 3,3'-(((3,3'-dimethyl-[1,1'-<br>biphenyl]-4,4'-diyl)bis(diazene-<br>2,1-diyl))bis(2-hydroxy-5,1-<br>phenylene))bis(4-(2,4-dimethyl<br>phenyl)-3,4,5a,6,9,9a-hexa hydro<br>benzo[e][1,3]oxazepine-1,5-<br>dione)                                                                                   | $C_{60}H_{48}N_6O_8$                                          | 980   | 230-232             | orange        | 63    | 23              | 0.54<br>(EtOAc: <i>n</i> -hexane)<br><b>3:1</b> |

## Table (2-3): The physical properties of compounds [A7-A12]

| $A_{10}$        | $H_{3}C$ $H$                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 3,3'-(((3,3'-dimethyl-[1,1'-<br>biphenyl]-4,4'-diyl)bis(diazene-<br>2,1-diyl))bis(2-hydroxy-5,1-<br>phenylene))bis(4-(4-methoxy<br>phenyl)octahydrobenzo[e][1,3]<br>oxazepine-1,5-dione)                                                                                                    | $C_{58}H_{44}N_6O_{10}$                                                       | 984  | 188-190 | dark<br>brown | 68 | 24 | 0.71<br>(EtOAc: <i>n</i> -hexane)<br><b>3:1</b> |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------|------|---------|---------------|----|----|-------------------------------------------------|
| A <sub>11</sub> | $HO \longrightarrow N=N \longrightarrow O-C \longrightarrow H$                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 3-(5-((4'-((3-(1,5-dioxo-4-phenyl<br>de cahydrobenzo[e][1,3]<br>oxazepin-3-yl)-4-hydroxy<br>Phenyl) diazenyl) -3,3'-di methyl<br>-[1,1'-biphenyl]-4-yl) diazenyl )-<br>2-hydroxyphenyl)-4-phenyl-<br>3,4,5a,6 ,9,9a-hexahydrobenzo<br>[e][1,3] oxazepine-1,5-dione                          | $C_{56}H_{40}N_6O_8$                                                          | 924  | 221-222 | orange        | 63 | 23 | 0.76<br>(EtOAc: <i>n</i> -hexane)<br><b>3:1</b> |
| A <sub>12</sub> | $HO \longrightarrow N=N \longrightarrow OH$ $O \longrightarrow C \longrightarrow H$ $O \longrightarrow O \longrightarrow O \longrightarrow H$ $O \longrightarrow O \longrightarrow H$ $O \longrightarrow O \longrightarrow O \longrightarrow H$ $O \longrightarrow O \longrightarrow H$ $O \longrightarrow O \longrightarrow H$ $O \longrightarrow O \longrightarrow O \longrightarrow O \longrightarrow H$ $O \longrightarrow O \longrightarrow O \longrightarrow H$ $O \longrightarrow $ | 4-(4-bromophenyl)-3-(5-((4'-((3-<br>(4-(4- bromophenyl)-1,5-dioxo<br>decahydrobenzo[e][1,3]oxazepin-<br>3-yl)-4-hydroxy phenyl)di<br>azenyl)-3,3'-di methyl -[1,1'-<br>biphenyl]-4-yl)di azenyl )-2-<br>hydroxy phenyl) -3,4,5a, 6,9,9a-<br>hexahydrobenzo [e] [1,3]<br>oxazepine-1,5-dione | C <sub>56</sub> H <sub>38</sub> N <sub>6</sub> O <sub>8</sub> Br <sub>2</sub> | 1082 | 245-247 | brown         | 73 | 22 | 0.78<br>(EtOAc: <i>n</i> -hexane)<br><b>3:1</b> |

#### 2.3.4.General procedure for synthesis of bisazobis -1,3-oxazepine-4,7dione derivatives [A<sub>13</sub>-A<sub>18</sub>]



Scheme (2-4): Synthesis of bisazo bis-1,3 oxazepine-4,7-dione derivatives [A13-A18]

A mixture of equimolar amounts of bis- azoimines  $[A_1-A_6]$  (0.0006 mol) and maleic anhydride (0.1176g, 0.0012 mol) in dry benzene (20 mL) was refluxed with stirring on a water bath at 75°C for (17-24h.). TLC (EtOAc :*n*- hexane, 2 : 1) showed that the reaction was completed. Then, the solvent was removed under reduced pressure and the resulting colored crystalline solid was washed well with ether and recrystallized from ethanol.

Table (2-4) shows the structures , molecular formulas , molecular weights , melting points, yield % and  $R_f$  values of the synthesized compounds [A<sub>13</sub>-A<sub>18</sub>].

Table (2-5) shows the (C.H.N.) elementary microanalysis data of the synthesized compounds  $[A_{13}-A_{18}]$ .

| <b>Table (2-4)</b> | : The physical | l properties of | compounds | [A13-A18] |
|--------------------|----------------|-----------------|-----------|-----------|
|--------------------|----------------|-----------------|-----------|-----------|

| Com.<br>no.     | Structural formula                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Name                                                                                                                                                                                        | M.F.                 | M.Wt<br>.g/mol | M.P. <sup>0</sup> C | Color         | Yield<br>% | R.T<br>( <i>h</i> .) | $\mathbf{R}_{f}$                                |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------|----------------|---------------------|---------------|------------|----------------------|-------------------------------------------------|
| A <sub>13</sub> |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 2,2'-(((3,3'-dimethyl-[1,1'-<br>biphenyl]-4,4'-diyl)bis<br>(diazene-2,1-diyl)) bis (2-<br>hydroxy-5,1-phenylene)) bis<br>(3-cyclohexyl-2,3-dihydro-1,3-<br>oxazepine-4,7-dione)             | $C_{48}H_{48}N_6O_8$ | 836            | 200-202             | brown         | 74         | 17                   | 0.81<br>(EtOAc: <i>n</i> -hexane)<br><b>3:1</b> |
| A <sub>14</sub> | HO - N=N - OH + H + O - OH + H + O - OH + H + O - OH + O - O - O - O - O - O - O - O - O - O                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 2,2'-(((3,3'-dimethyl-[1,1'-<br>biphenyl]-4,4'-diyl) bis<br>(diazene-2,1-diyl)) bis (2-<br>hydroxy-5,1-phenylene)) bis(<br>3-(phenylamino)-2,3-di hydro-<br>1,3-oxazepine-4,7-dione)        | C48H38N8O8           | 854            | 203-205             | dark<br>brown | 59         | 24                   | 0.63<br>(EtOAc: <i>n</i> -hexane)<br><b>3:1</b> |
| A <sub>15</sub> | $HO \longrightarrow H_3C \longrightarrow CH_3 \longrightarrow OH H_3C \longrightarrow OH H_3C \longrightarrow CH_3 \longrightarrow OH H_3C \longrightarrow OH H_$ | 2,2'- ((((3,3'-dimethyl-[1,1'-<br>biphenyl]-4,4'-diyl)bis (di<br>azene-2,1-diyl)) bis(2-hydroxy<br>-5,1-phenylene)) bis(3-(2,4-<br>dimethylphenyl)-2,3-dihydro-<br>1,3-oxazepine-4,7-dione) | $C_{52}H_{44}N_6O_8$ | 880            | 176-177             | orange        | 66         | 21                   | 0.58<br>(EtOAc: <i>n</i> -hexane)<br><b>3:1</b> |

| $A_{16}$        | $H_{3}C$<br>$H_{3}C$<br>$H_{3}C$<br>$H_{3}C$<br>$H_{3}C$<br>$H_{3}C$<br>$H_{3}C$<br>$H_{3}C$<br>$H_{3}C$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>$CH_{3}$<br>C                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 2,2'-(((3,3'-dimethyl-[1,1'-bi<br>phenyl]-4,4'-diyl)bis(diazene-<br>2,1-diyl))bis(2-hydroxy-5,1-<br>phenylene))bis(3-(4-methoxy<br>phenyl)-2,3-dihydro-1,3-<br>oxazepine-4,7-dione) | $C_{50}H_{40}N_6O_{10}$                                                       | 884 | 185 -187 | brown | 63 | 20 | 0.77<br>(EtOAc: <i>n</i> -hexane)<br><b>3:1</b> |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------|-----|----------|-------|----|----|-------------------------------------------------|
| A <sub>17</sub> | HO - V = N = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V = N - V =                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 2,2'-(((3,3'-dimethyl-[1,1'-bi<br>phenyl]-4,4'-diyl)bis(diazene-<br>2,1-diyl))bis(2-hydroxy-5,1-<br>phenylene))bis(3-phenyl-2,3-<br>dihydro-1,3-oxazepine-4,7-<br>dione)            | $C_{48}H_{36}N_6O_8$                                                          | 824 | 217-219  | red   | 63 | 21 | 0.65<br>(EtOAc: <i>n</i> -hexane)<br><b>3:1</b> |
| A <sub>18</sub> | $HO \longrightarrow N=N \longrightarrow OH$ $O \xrightarrow{C-H} OH$ | 2,2'-(((3,3'-dimethyl-[1,1'-bi<br>phenyl]-4,4'-diyl)bis(diazene-<br>2,1-diyl))bis(2-hydroxy-5,1-<br>phenylene))bis(3-(4-bromo<br>phenyl)-2,3-dihydro-1,3-<br>oxazepine-4,7-dione)   | C <sub>48</sub> H <sub>34</sub> N <sub>6</sub> O <sub>8</sub> Br <sub>2</sub> | 982 | 235-237  | red   | 61 | 22 | 0.68<br>(EtOAc: <i>n</i> -hexane)<br><b>3:1</b> |

| Com.            | M.Wt. |       | Calculated / For | ınd   |
|-----------------|-------|-------|------------------|-------|
| no.             | g/mol | C %   | Н %              | N %   |
| Δ7              | 936   | 71.79 | 5.55             | 8.97  |
| 11/             |       | 71.10 | 5.38             | 8.45  |
| A <sub>8</sub>  | 954   | 70.44 | 4.40             | 11.74 |
| 0               |       | 69.75 | 4.12             | 11.32 |
| A <sub>9</sub>  | 980   | 73.46 | 4.89             | 8.57  |
|                 |       | 73.17 | 4.48             | 8.93  |
| $A_{10}$        | 984   | 70.73 | 4.47             | 8.53  |
|                 |       | 70.38 | 4.28             | 8.34  |
| A <sub>11</sub> | 924   | 72.72 | 4.32             | 9.09  |
|                 |       | 72.48 | 4.21             | 8.53  |
| A <sub>12</sub> | 1082  | 62.10 | 3.51             | 7.76  |
|                 |       | 61.55 | 2.86             | 6.09  |
| A <sub>13</sub> | 836   | 68.89 | 5.74             | 10.04 |
|                 |       | 68.23 | 5.14             | 10.24 |
| $A_{14}$        | 854   | 67.44 | 4.44             | 13.11 |
|                 |       | 67.15 | 4.03             | 12.92 |
| A <sub>15</sub> | 880   | 70.90 | 5.00             | 9.54  |
|                 |       | 70.50 | 5.05             | 9.10  |
| A <sub>16</sub> | 884   | 67.87 | 4.52             | 9.50  |
|                 |       | 67.24 | 4.16             | 9.22  |
| A <sub>17</sub> | 824   | 69.90 | 4.36             | 10.19 |
|                 |       | 69.33 | 4.19             | 9.91  |
| <b>A</b> 10     | 982   | 58.65 | 3.46             | 8.55  |
| 4 18            |       | 58.05 | 3.62             | 8.28  |

# Table (2-5): (C.H.N.) analysis data of bisazobis -1,3- oxazepine-4,7-<br/>dione derivatives [A7. A18]



#### 2.3.5. General procedure for Synthesis of bis imine derivatives [B<sub>1</sub>-B<sub>5</sub>]

Scheme (2-5) : Synthesis of bisimines [B<sub>1</sub> - B<sub>5</sub>]

*o*-Toludine (1.06g ,0.005mol) was dissolved in absolute ethanol (20mL) containing two drops of glacial acetic acid, then equimolar amount (0.010mol) of aromatic aldehydes (2,5-dimethoxybenzaldehyde , 4-chlorobenzaldehyde , benzaldehyde, 2-hydroxybenzaldehyde and 4-*N*,*N*-dimethylaminobenzaldehyde) were added. The reaction mixture was refluxed with stirring on a water bath at 70°C for (3-4 h.) . TLC (Et<sub>2</sub>O: *n*-hexane , 2 : 1) showed that the reaction was completed . The mixture was then allowed to cool down to room temperature and the colored precipitate was filtered , then recrystallized from ethanol.

Table (2-6) shows the structures , molecular formulas, molecular weights, melting points, yield % and  $R_f$  values of the synthesized compounds  $[B_1-B_5]$ .

## Table (2-6) : The physical properties of compounds [B1-B5]

| Com.<br>no.           | Structural formula                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Name                                                                                                              | M.F.                  | M.W<br>t.<br>g/mol | M.P.ºC        | Color              | Yiel<br>d % | <b>R.T.</b> ( <i>h</i> .) | $\mathbf{R}_{f}$                                     |
|-----------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------|-----------------------|--------------------|---------------|--------------------|-------------|---------------------------|------------------------------------------------------|
| $\mathbf{B}_1$        | CH3 H3CO<br>H3CO<br>H3CO<br>H3CO<br>H3CO<br>H3CO<br>H3CO<br>H3CO                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | N4,N4'-bis(2,5-dimethoxy<br>benzylidene)-3,3'-di<br>methyl -[1,1'-biphenyl]-<br>4,4'-diamine                      | $C_{32}H_{32}N_2O_4$  | 508                | 188 -186      | Pale<br>green      | 92          | 3                         | 0.73<br>(Et <sub>2</sub> O: <i>n</i> -hexane)<br>2:1 |
| <b>B</b> <sub>2</sub> |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | N4,N4'-bis(4-chloro<br>benzylidene)-3,3'-<br>dimethyl-[1,1'-biphenyl]-<br>4,4'-diamine                            | $C_{28}H_{22}N_2Cl_2$ | 457                | 138-142       | dark<br>green      | 64          | 3.25                      | 0.79<br>(Et <sub>2</sub> O: <i>n</i> -hexane)<br>2:1 |
| <b>B</b> <sub>3</sub> |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | N4,N4'-dibenzylidene-<br>3,3'-dimethyl-[1,1'-<br>biphenyl]-4,4'-diamine                                           | $C_{28}H_{24}N_2$     | 388                | 161-163       | Greenish<br>yellow | 86          | 3.5                       | 0.81<br>(Et <sub>2</sub> O: <i>n</i> -hexane)<br>2:1 |
| <b>B</b> <sub>4</sub> |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 2,2'-((((3,3'-dimethyl-[1,1'-<br>biphenyl]-4,4'-diyl)<br>bis(azanylylidene))<br>bis(methanylylidene))<br>diphenol | $C_{28}H_{24}N_2O_2$  | 420                | 198-202       | yellow             | 76          | 4                         | 0.82<br>(Et <sub>2</sub> O: <i>n</i> -hexane)<br>2:1 |
| <b>B</b> 5            | $H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$ $H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>$H_3C$<br>H | N4,N4'-bis(4-<br>(dimethylamino)benzylide<br>ne)-3,3'-dimethyl-[1,1'-<br>biphenyl]-4,4'-diamine                   | $C_{32}H_{34}N_4$     | 474                | 260<br>(dec.) | red                | 83          | 4                         | 0.76<br>(Et <sub>2</sub> O: <i>n</i> -hexane)<br>2:1 |

#### 2.3.6.General procedure for synthesis of bis-1,3-oxazepine-4,7-dione derivatives [B<sub>6</sub>- B<sub>10</sub>]



Scheme (2-6) : Synthesis of bis-1,3-oxazapine-4,7-dione derivatives [B<sub>6</sub>-B<sub>10</sub>]

A mixture of equimolar amounts of Schiff bases derivatives  $[B_1-B_5]$  (0.0006 mol) and phthalic anhydride (0.1776 g ,0.0012mol) in dry benzene (20 mL) was refluxed with stirring on a water bath at 60<sup>o</sup>C for (6-8 h.) .TLC (EtOAc : *n*-hexane , 2 : 1) showed that the reaction was completed . Then, the solvent was removed under reduced pressure and the resulting colored crystalline solid was recrystallized from ethanol .

Table (2-7) shows the structures , molecular formulas , molecular weights , melting points, yield % and  $R_f$  values of the synthesized compounds [ $B_6$ - $B_{10}$ ].

The (C.H.N.) elementary microanalysis data of the synthesized compounds  $[B_6-B_{10}]$  was lisited in table (2-9)

### Table (2-7) : The physical properties of compounds [B<sub>6</sub>-B<sub>10</sub>]

| Com.<br>no.           | Structural formula                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Name                                                                                                                                       | <b>M.F.</b>               | M.Wt.<br>g/mol | M.P.ºC  | Color          | Yield<br>% | <b>R.T.</b> ( <i>h</i> .) | $\mathbf{R}_{f}$                                |
|-----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------|---------------------------|----------------|---------|----------------|------------|---------------------------|-------------------------------------------------|
| B <sub>6</sub>        | $H_{3}CO$ $OCH_{3}$ $H_{3}C$ $CH_{3}$ $H_{3}CO$ $H_{3}C$                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 4,4'-(3,3'-dimethyl-[1,1'-<br>biphenyl]-4,4'-diyl)bis(3-(2,5-<br>dimethoxyphenyl)-3,4-<br>dihydro benzo [e][1,3]<br>oxazepine-1,5-dione)   | $C_{48}H_{40}N_2O_{10}\\$ | 804            | 216-218 | grew           | 73         | 6                         | 0.86<br>(EtOAc: <i>n</i> -hexane)<br><b>2:1</b> |
| <b>B</b> <sub>7</sub> |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 4,4'-(3,3'-dimethyl-[1,1'-<br>biphenyl]-4,4'-diyl)bis(3-(4-<br>chlorophenyl)-3,4-dihydro<br>benzo [e][1,3]oxazepine-1,5-<br>dione)         | $C_{44}H_{30}N_2O_6Cl_2$  | 753            | 240-242 | Pale<br>yallow | 68         | 6.25                      | 0.61<br>(EtOAc: <i>n</i> -hexane)<br><b>2:1</b> |
| $B_8$                 | H <sub>3</sub> C<br>CH <sub>3</sub><br>CH <sub>3</sub><br>C<br>C<br>C<br>C<br>C<br>C<br>C<br>C<br>C<br>C<br>C<br>C<br>C<br>C<br>C<br>C<br>C<br>C<br>C | 4,4'-(3,3'-dimethyl-[1,1'-<br>biphenyl]-4,4'-diyl)bis(3-<br>phenyl-3,4-dihydrobenzo[e]<br>[1,3]oxazepine-1,5-dione)                        | $C_{44}H_{32}N_2O_6$      | 684            | 225-228 | grew           | 71         | 7                         | 0.76<br>(EtOAc: <i>n</i> -hexane)<br><b>2:1</b> |
| B9                    | OH HC H3 OC OC OC                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 4,4'-(3,3'-dimethyl-[1,1'-<br>biphenyl]-4,4'-diyl)bis(3-(2-<br>hydroxyphenyl)-3,4-di<br>hydrobenzo[e][1,3]<br>oxazepine-1,5-dione)         | $C_{44}H_{32}N_2O_8$      | 716            | 212-214 | orange         | 59         | 7.5                       | 0.83<br>(EtOAc: <i>n</i> -hexane)<br><b>2:1</b> |
| B <sub>10</sub>       | $H_3C$ $H_3C$ $CH_3$ $H_3C$ $CH_3$ $H_3C$ $CH_3$                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 4,4'-(3,3'-dimethyl-[1,1'-bi<br>phenyl]-4,4'-diyl)bis(3-(4-(di<br>methylamino)phenyl)-3,4-di<br>hydrobenzo[e][1,3]<br>oxazepine-1,5-dione) | $C_{48}H_{42}N_4O_6$      | 770            | 238-240 | red            | 78         | 8                         | 0.59<br>(EtOAc: <i>n</i> -hexane)<br><b>2:1</b> |

## 2.3.7.General procedure for Synthesis of bis -1,3-oxazepine-4,7-dione derivatives [B<sub>11</sub>-B<sub>15</sub>]



Scheme (2-7): Synthesis of bis-1,3-oxazapine-4,7-dione derivatives [B11-B15]

Amixture of equimolar amounts (0.0006 mol) of Schiff bases derivatives  $[B_1-B_5]$  and maleic anhydride (, 0.1176g ,0.0012 mol) in dry benzene (20 mL) was refluxed with stirring on a water bath at 60°C for (5-7 h.) . TLC (ethyl acetate :*n* -hexane , 2 : 1) showed that the reaction was completed . Then, the solvent was removed under reduced pressure and the resulting colored crystalline solid was recrystallized from ethanol .

Table (2-8) shows the structures, molecular formulas, molecular weights, melting points, yield % and  $R_f$  values of the synthesized compounds  $[B_{11}-B_{15}]$ .

Table (2-9) shows the (C.H.N.) elementary microanalysis data of the synthesized compounds  $[B_{11}-B_{15}]$ .

## Table (2-8) : The physical properties of compounds [B<sub>11</sub>-B<sub>15</sub>]

| Com.<br>no.            | Structural formula                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Name                                                                                                                              | M.F.                     | M.Wt.<br>g/mol | M.P.ºC        | Color          | Yield<br>% | R.T.<br>(h.) | $\mathbf{R}_{f}$                                |
|------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------|--------------------------|----------------|---------------|----------------|------------|--------------|-------------------------------------------------|
| B <sub>11</sub>        | H <sub>3</sub> CO<br>H <sub></sub> | 3,3'-(3,3'-dimethyl-[1,1'-<br>biphenyl]-4,4'-diyl) bis<br>(2-(2,5-dimethoxyphenyl)<br>-2,3-dihydro-1,3-<br>oxazepine-4,7-dione)   | $C_{40}H_{36}N_2O_{10}$  | 704            | 178<br>(dec.) | orange         | 78         | 5            | 0.63<br>(EtOAc: <i>n</i> -hexane)<br><b>2:1</b> |
| <b>B</b> <sub>12</sub> |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 3,3'-(3,3'-dimethyl-[1,1'-<br>biphenyl]-4,4'-diyl)bis(2-<br>(4-chlorophenyl)-2,3-<br>dihydro-1,3-oxazepine-<br>4,7-dione)         | $C_{36}H_{26}N_2O_6Cl_2$ | 653            | 196<br>(dec.) | Pale<br>yellow | 82         | 6            | 0.69<br>(EtOAc: <i>n</i> -hexane)<br><b>2:1</b> |
| <b>B</b> <sub>13</sub> | H <sub>3</sub> C<br>CH <sub>3</sub><br>CH                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 3,3'-(3,3'-dimethyl-[1,1'-<br>biphenyl]-4,4'-diyl)bis(2-<br>phenyl-2,3-dihydro-1,3-<br>oxazepine-4,7-dione)                       | $C_{36}H_{28}N_2O_6$     | 584            | 198<br>(dec.) | grew           | 73         | 6            | 0.71<br>(EtOAc: <i>n</i> -hexane)<br><b>2:1</b> |
| <b>B</b> <sub>14</sub> | CH <sub>3</sub> C <sub>H3</sub> H0<br>H <sub>3</sub> C <sub>H3</sub> H0<br>N-C <sub>0</sub><br>O                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 3,3'-(3,3'-dimethyl-[1,1'-<br>biphenyl]-4,4'-diyl)bis(2-<br>(2-hydroxyphenyl)-2,3-<br>dihydro-1,3-oxazepine-<br>4,7-dione)        | $C_{36}H_{28}N_2O_8$     | 616            | 195<br>(dec.) | grew           | 61         | 6.5          | 0.66<br>(EtOAc: <i>n</i> -hexane)<br><b>2:1</b> |
| B <sub>15</sub>        | $H_3C$                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 3,3'-(3,3'-dimethyl-[1,1'-<br>biphenyl]-4,4'-diyl) bis<br>(2(4-(dimethylamino)<br>phenyl)-2,3-dihydro-1,3-<br>oxazepine-4,7-dione | $C_{40}H_{38}N_4O_6$     | 670            | 162-164       | red            | 87         | 7            | 0.76<br>(EtOAc: <i>n</i> -hexane)<br><b>2:1</b> |

| Com.                   | M.Wt. | Calculated /Found |      |      |  |  |  |
|------------------------|-------|-------------------|------|------|--|--|--|
| ,                      |       | С %               | Н %  | N %  |  |  |  |
| P.                     | 804   | 71.64             | 4.97 | 3.48 |  |  |  |
| $\mathbf{D}_6$         | 804   | 71.09             | 5.04 | 3.42 |  |  |  |
| B <sub>2</sub>         | 753   | 70.11             | 3.98 | 3.71 |  |  |  |
| <b>D</b> 7             |       | 70.74             | 4.85 | 3.96 |  |  |  |
| Ba                     | 684   | 77.19             | 4.67 | 4.09 |  |  |  |
| <b>D</b> 8             |       | 77.68             | 4.34 | 4.23 |  |  |  |
| Bo                     | 716   | 73.74             | 4.46 | 3.91 |  |  |  |
| <b>D</b> 9             |       | 73.49             | 4.48 | 3.77 |  |  |  |
| <b>B</b> 10            | 770   | 74.80             | 5.45 | 7.27 |  |  |  |
| <b>D</b> 10            |       | 74.55             | 5.56 | 7.09 |  |  |  |
| <b>B</b> 11            | 704   | 68.18             | 5.11 | 3.97 |  |  |  |
| DII                    |       | 68.45             | 5.43 | 4.88 |  |  |  |
| B <sub>12</sub>        | 653   | 66.15             | 3.98 | 4.28 |  |  |  |
| <b>D</b> <sub>12</sub> | 000   | 66.23             | 4.38 | 4.41 |  |  |  |
| <b>B</b> 12            | 584   | 73.97             | 4.79 | 4.79 |  |  |  |
| <b>D</b> <sub>13</sub> |       | 73.75             | 4.42 | 4.52 |  |  |  |
| B <sub>1</sub> ,       | 616   | 70.12             | 4.54 | 4.54 |  |  |  |
| <b>D</b> <sub>14</sub> | 010   | 69.24             | 4.13 | 4.28 |  |  |  |
| R.c.                   | 670   | 71.64             | 5.67 | 8.35 |  |  |  |
| <b>D</b> 15            | 0/0   | 70.65             | 5.62 | 8.31 |  |  |  |

# Table (2-9) : (C.H.N.) analysis data of bis -1,3- oxazepine-4,7- dione derivatives [B<sub>6</sub>-B<sub>15</sub>]


#### **3-** Results and Discussion

# **3.1.** Synthesis of 5,5'-((3,3'-dimethyl-[1,1'-biphenyl]-4,4'-diyl) bis(diazene-2,1diyl))bis (2-hydroxybenzaldehyde) [A]

A coupling reaction between the bis diazonium salt of *o*- toludine and equimolar quantity of phenoxide salt of 2-hydroxybenzaldehyde as coupling reagent at (0-5)°C afforded bis-azoaldehyde derivative<sup>(92)</sup> [A] as indicated in scheme (3-1).



Scheme (3-1) : Synthesis of bis-azoaldehyde derivative [A]

The coupling reaction is an electrophilic substitution in aromatic systems which proceeds according to the proposed mechanism<sup>(93)</sup> shown in schemes (3-2 and 3-2a).



Scheme (3-2): Mecansim of formation of *o* - tolidylbisdiazonium cation



Scheme(3-2a): Mechanism of coupling reaction

The FT-IR spectra, figure (3-2) of bis-azoaldehyde derivative [A] showed disappearance of the sharp bands at (3468,3410) cm<sup>-1</sup> and (3373,3338) cm<sup>-1</sup> attributed to the asymmetric and symmetric stretching vibrations of amino groups (-NH<sub>2</sub>) in *o*-toludine, the spectrum also showed disappearance of the sharp and strong band at 1624 cm<sup>-1</sup> due to the scissoring bending vibration of (-NH<sub>2</sub>) groups and appearance of sharp and strong band at 1653cm<sup>-1</sup>assigned to the stretching vibration of carbonyl groups<sup>(94)</sup>(C=O), this band was shifted towards lower frequency due to intramolecular hydrogen bonding with *ortho*-hydroxy group<sup>(95)</sup>, the spectrum also appeared broad band at 3416cm<sup>-1</sup> attributed to the stretching vibration of hydroxy group. Other bands with their interpretation were summarized in table (3-1).

### **3.2.** Synthesis of bis-azoimine derivatives [A<sub>1</sub>-A<sub>6</sub>]

A condensation reactions between bis-azoaldehyde derivative [A] and some selective primary amines and a hydrazine (cyclohexyl amine, phenylhydrazine, 2,4-dimethylaniline, 4-methoxyaniline, aniline and 4bromoaniline) respectively in the presence of two drops of glacial acetic acid as catalyst in absolute ethanol resulted formation of bis-azoimines  $[A_1-A_6]$  as shown in scheme (3-3).



Scheme (3-3) : Synthesis of bis – azoimine derivatives [A1-A6]

The condensation reaction  $^{(96)}$  proceeds via elimination of two H<sub>2</sub>O molecules as shown in the following proposed mechanism .Scheme (3-4).



Scheme (3-4): Mechanism of formation of bis-azoimines  $[A_1-A_6]$ 

FT-IR spectrum, figures (3-3) - (3-8) at  $\mathbf{v}$  (cm<sup>-1</sup>) (KBr) of all synthesized bis-azoimines compounds [A<sub>1</sub>-A<sub>6</sub>] illustrate good evidence that the reactions happened successfully by disappearing the strong band at 1653cm<sup>-1</sup> belong to the stretching vibration of (C=O) group and appearing strong band at lower frequencies at the general range (1629-1600) cm<sup>-1</sup>attributed to the stretching vibration of imine groups<sup>(97)</sup>(C=N). Other characteristic bands with their interpretation were summarized in table (3-1).

Table (3-1): FT-IR data of the synthesized bis - azoimine derivatives

 $[A_1-A_6]$  in cm<sup>-1</sup>

| Com.<br>no.    | FT-IR bands                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| [A]            | 3416 and 3251 ( $\upsilon_{O-H}$ ), 3045 ( $\upsilon_{C-H,benzene rings}$ ), 2922 ( $\upsilon_{as.C-Hm,CH^3}$ ),<br>2835 ( $\upsilon_{s.C-H,CH^3}$ ),2758( $\upsilon_{C-H,aldehyde}$ ),1653 ( $\upsilon_{C=O}$ ),1602, 1518 and<br>1471( $\upsilon_{C=C,benzene rings}$ ),1461( $\delta_{as.C-H, CH^3}$ ),1375( $\delta_{s.C-H, CH^3}$ ),1329<br>and1278 ( $\upsilon_{C-N}$ ),1103( $\upsilon_{C-O,phenol}$ ),895,837,756 and 698( $\delta_{o.o.p}$ C-H,<br>benzene rings).         |
| A <sub>1</sub> | 3444 ( $\upsilon_{O-H}$ ),3036 ( $\upsilon_{C-H}$ , benzene rings),2928 ( $\upsilon_{as\cdot C-H,CH2,cyclohexane}$ ),<br>2854 ( $\upsilon_{s\cdot C-H,CH2,cyclohexane}$ ),1629 ( $\upsilon_{C=N}$ ), 1598 and 1489( $\upsilon_{C=C}$ ,<br>benzene rings),1448 ( $\delta_{sciss\cdot C-H,CH2,cyclohexane}$ ),1379 ( $\delta_{s\cdot C-H,CH3}$ ),1346 and<br>1284 ( $\upsilon_{C-N}$ ),1103( $\upsilon_{C-O,phenol}$ ), 889,833,749 and 692( $\delta_{o.o.p}$ C-H,<br>benzene rings). |
| $\mathbf{A}_2$ | 3423 ( $\upsilon_{O-H}$ ) ,3307( $\upsilon_{N-H}$ ) ,3034 and 3001 ( $\upsilon_{C-H, benzene rings}$ ),2943 ( $\upsilon_{as\cdot C-H,CH^3}$ ), 2899 ( $\upsilon_{s\cdot C-H,CH^3}$ ), 1600 ( $\upsilon_{C=N}$ ),1572 and1489 ( $\upsilon_{C=C,benzene rings}$ ),1442( $\delta_{s\cdot C-H,CH^3}$ ),1398( $\delta_{s\cdot C-H,CH^3}$ ),1348 and 1288 ( $\upsilon_{C-N}$ ),1105( $\upsilon_{C-O,phenol}$ ),852,827,786,746 and 690( $\delta_{o.o.p}$ C-H,benzene rings).              |

| <b>A</b> 3            | 3435( $\upsilon_{O-H}$ ),3037 and 3010 ( $\upsilon_{C-H,benzene rings}$ ),2970 ( $\upsilon_{as.C-H,CH^3}$ ), 2872 ( $\upsilon_{s.C-H,CH^3}$ ),2812 ( $\upsilon_{C-H,imine}$ ),1612 ( $\upsilon_{C=N}$ ),1582and1487( $\upsilon_{C=C, benzene rings}$ ),1442 ( $\delta_{as.C-H, CH^3}$ ),1396 ( $\delta_{s.C-H,CH^3}$ ), 1350, 1282 ( $\upsilon_{C-N}$ ), 1105( $\upsilon_{C-O,phenol}$ ),896,835,823,717 and 671( $\delta_{o.o.p. C-H, benzene rings}$ ).                                                  |
|-----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| A4                    | 3433 ( $\upsilon_{O-H}$ ), 3041 and 3001( $\upsilon_{C-H,benzene rings}$ ), 2943 ( $\upsilon_{as.C-H,CH^3}$ ),2899 ( $\upsilon_{s.C-H,CH^3}$ ),2833 ( $\upsilon_{C-H,imine}$ ), 1618 ( $\upsilon_{C=N}$ ), 1599,1506 and 1485 ( $\upsilon_{C=C,benzene rings}$ ),1442 ( $\delta_{as.C-H, CH3}$ ),1398( $\delta_{s.C-H,CH^3}$ ) 1348 and 1288 ( $\upsilon_{C-N}$ ),1105 ( $\upsilon_{C-O,phenol}$ ),1031 ( $\upsilon_{s.C-O-C,ether}$ ) 902, 877, 835, 788,756and717( $\delta_{o.o.p C-H,benzene rings}$ ). |
| <b>A</b> 5            | 3431( $\upsilon_{O-H}$ ), 3034 ( $\upsilon_{C-H, benzene rings}$ ), 2920 ( $\upsilon_{as.C-H,CH^3}$ ),2848 ( $\upsilon_{s.C-H,CH^3}$ ),1618 ( $\upsilon_{C=N}$ ), 1593, 1572 and 1485 ( $\upsilon_{C=C,benzene rings}$ ),1456 ( $\upsilon_{as.C-H, CH^3}$ ),1438 ( $\upsilon_{N=N}$ ),1398 ( $\upsilon_{s.C-H, CH^3}$ ),1350 and 1282 ( $\upsilon_{C-N}$ ), 1103 ( $\upsilon_{C-O,phenol}$ ),895,871,821, 783, 758 and 690 ( $\delta_{o.o.p.C-H, benzene rings}$ ).                                        |
| <b>A</b> <sub>6</sub> | 3433 ( $\upsilon_{O-H}$ ),3041 ( $\upsilon_{C-H,benzene rings}$ ), 2953 ( $\upsilon_{as.C-H,CH^3}$ ), 2922 ( $\upsilon_{s.C-H,CH^3}$ ),1616 ( $\upsilon_{C=N}$ ), 1587, 1572 and 1483 ( $\upsilon_{C=C,benzene rings}$ ), 1458 ( $\delta_{as.C-H, CH^3}$ ),1435 ( $\upsilon_{N=N}$ ),1394 ( $\delta_{s.C-H, CH^3}$ ),1350 and 1282 ( $\upsilon_{C-N}$ ), 1103 ( $\upsilon_{C-O,phenol}$ ),1072 ( $\upsilon_{C-Br}$ ), 889, 875, 825, 777, 740 and 694 ( $\delta_{o.o.p.C-H,benzene rings}$ ).              |

## 3.3.Synthesis of bisazobis -1,3-oxazepine-4,7-dione derivatives [A7-A12]

This series of bis-1,3-oxazepine derivatives was obtained via a  $(5+2 \rightarrow 7)$  cycloaddition reaction between equimolar amount of phathalic anhydride as five-membered component and the synthesized bis-azoimines [A<sub>1</sub>-A<sub>6</sub>] as two-membered components<sup>(98)</sup> in dry benzene as indicated in scheme (3-5).



Scheme (3-5) : Synthesis of bisazo bis -1,3 oxazepine- 4,7-dione derivatives [A7-A12]

This type of cycloaddition reactions involves addition of five atom from the first compnent (Maleic anhydride) to two atoms from the second compnent (imine group) to form a seven-membered 1,3-oxazepine ring.The cycloaddition is believed to proceed via formation of four-membered cyclic transition state (i.e.concerted process)<sup>(99)</sup> in which the participating orbitals should be in the same plane<sup>(100)</sup> as indicated in scheme (3-6).



Scheme (3-6) : Approximate transition state geometryfor addition of Maleic anhydride to imine groups

The (C.H.N.) elementery microanalysis, table (2-5) of bisazo bis -1,3 oxazepines  $[A_7-A_{12}]$  showed good agreement between the calculated and found values.

The FT-IR spectrum, figures (3-9) - (3-14) of compounds  $[A_7-A_{12}]$  illustrate good evidence that the cycloaddition reactions happened successfully through disappearing the strong band at the general range (1629-1600) cm<sup>-1</sup> which attributed to v (C=N) and appearing of one or two bands at frequency relatively higher than that of (C=N) group at (1714 and 1656) cm<sup>-1</sup>,1693cm<sup>-1</sup>,1689cm<sup>-1</sup>,1691cm<sup>-1</sup>,(1707and1680) cm<sup>-1</sup>,(1716 and 1649) cm<sup>-1</sup>and (1716and1656) respectively attributed to the stretching vibrations of carbonyl groups (O=C-O) and (O=C-N) inside oxazepine ring respectively.It is important to refer that appearance only one band for (C=O) groups insideoxazepine ring due to the vibration coupling interactions. Other caracteristic bands with their interpretation were summarized in table (3-2).

Table (3-2): FT-IR data of the synthesized bisazo bis -1,3-oxazepine-4,7dione derivatives [A<sub>7</sub>-A<sub>12</sub>]

| Com.<br>no.     | FT-IR bands                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>A</b> 7      | 3363 ( $\upsilon_{O-H}$ ), 3051 ( $\upsilon_{C-H,benzene rings}$ ),2928 ( $\upsilon_{as.C-H,CH^2,cyclohexane}$ )<br>,2854 ( $\upsilon_{s.C-H,CH^2,cyclohexane}$ ), 1714 ( $\upsilon_{C=O,O=C-O,oxazepine}$ ), 1656 ( $\upsilon_{C=O,O=C-N,oxazepine}$ ),1597 and 1481( $\upsilon_{C=C,benzene rings}$ ), 1452 ( $\delta_{sciss}$ ·C-H,CH <sup>2</sup> cyclohexane), 1371( $\delta_{s.C-H,CH^3}$ ), 1278 ( $\upsilon_{C-N}$ ), 1103 ( $\upsilon_{C-O,phenol}$ ),891, 831,759 and 702 ( $\delta_{o.o.p.C-H,benzene rings}$ ).                            |
| <b>A</b> 8      | 3497 ( $\upsilon_{O-H}$ ), 3288 ( $\upsilon_{N-H}$ ), 3034 ( $\upsilon_{C-H,benzene rings}$ ), 2953 ( $\upsilon_{as.C-H,CH3}$ )<br>,2874 ( $\upsilon_{s.C-H,CH3}$ ), 1693 ( $\upsilon_{C=O,O=C-OandO=C-N,oxazepine, vib.coupling$ ),<br>1597,1572 and 1487 ( $\upsilon_{C=C,benzene rings}$ ), 1396 ( $\delta_{s.C-H, CH3}$ ), 1274<br>( $\upsilon_{C-N}$ ), 1115 ( $\upsilon_{C-O,phenol}$ ), 806,748,694 ( $\delta_{o.o.p.C-H, benzene rings}$ ).                                                                                                    |
| A9              | 3406( $\upsilon_{O-H}$ ), 3080and 3012( $\upsilon_{C-H}$ , benzene rings),2974( $\upsilon_{as. C-H,CH^3}$ )<br>,2897 ( $\upsilon_{s.C-H,CH^3}$ ), 2816( $\upsilon_{C-H,oxazepine}$ ), 1691 ( $\upsilon_{C=O,O=C-O}$ and O=C-N<br>,oxazepine,vib.coupling), 1587 and 1404 ( $\upsilon_{C=C,benzene rings}$ ),1494( $\upsilon_{as.NO^2}$ ),<br>1280 ( $\upsilon_{C-N}$ ),1070 ( $\upsilon_{C-O,phenol}$ ),908,829,800,740 and 673( $\delta_{o.o.p.C-H}$ ,<br>benzene rings).                                                                             |
| A10             | 3427( $\upsilon_{O-H}$ ), 3101and 3014( $\upsilon_{C-H}$ , benzene rings),2923 ( $\upsilon_{as. C-H,CH^3}$ )<br>,2870( $\upsilon_{s.C-H,CH^3}$ ), 1707 ( $\upsilon_{C=O,O=C-O}$ , oxazepine), 1680( $\upsilon_{C=O,O=C-N}$ , oxazepine),1514( $\upsilon_{C=C,benzene}$ rings),1394( $\delta_{s.C-H,CH^3}$ ), 1284and1255( $\upsilon_{C-N}$ ),1072( $\upsilon_{C-O,phenol}$ ),1030( $\upsilon_{s.C-O-C,ether}$ ) 902, 827,787,759 and 702 ( $\delta_{o.o.p.C-H,benzene}$ rings).                                                                        |
| A <sub>11</sub> | 3319 ( $\upsilon_{O-H}$ ),3130 and 3055 ( $\upsilon_{C-H, \text{ benzene rings}}$ ),2985 and 2923( $\upsilon_{as}$ .<br>C-H,CH <sup>3</sup> ),2875( $\upsilon_{s-C-H,CH^3}$ ),1716 ( $\upsilon_{C=O,O=C-O,oxazepine}$ ),1649 ( $\upsilon_{C=O,O=C-O,oxazepine}$ ), 1602,1543,1506,1491 and 1454( $\upsilon_{C=C,benzenerings}$ ), 1440<br>( $\delta_{as}$ -C-H, CH <sup>3</sup> ), 1394( $\delta_{s-C-H,CH^3}$ ), 1330 and 1242 ( $\upsilon_{C-N}$ ), 1087 ( $\upsilon_{-C-O,oxazepine}$ ), 891,827,750 and 690 ( $\delta_{o.o.p.C-H,benzenerings}$ ). |
| A <sub>12</sub> | 3315( $\upsilon_{O-H}$ ), 3055 ( $\upsilon_{C-H,benzene rings}$ ), 2924 ( $\upsilon_{as\cdot C-H,CH^3}$ ),2860 ( $\upsilon_{s\cdot C-H}$ ,CH <sup>3</sup> ), 1716( $\upsilon_{C=O,O=C-O,oxazepine}$ ),1656( $\upsilon_{C=O,O=C-N,oxazepine}$ ), 1610,1548 and 1485 ( $\upsilon_{C=C}$ ),1386 ( $\delta_{s\cdot C-H,CH^3}$ ) 1282 and 1247 ( $\upsilon_{C-N}$ ),1111( $\upsilon_{C-O,phenol}$ ), 1074 ( $\upsilon_{C-Br}$ ),885, 819, 796, 763, 732 and 698 ( $\delta_{o.o.p.C-H,benzene rings}$ ).                                                     |

#### 3.4. Synthesis of bisazobis -1,3-oxazepine-4,7-dione derivatives [A<sub>13</sub>-A<sub>18</sub>]

The synthesized bisimines  $[A_1-A_6]$  were also introduced in  $(5+2 \longrightarrow 7)$  cycloaddition reaction with maleic anhydride as five-membered component to obtain a second series of bis-1,2-disubstituted-1,3-oxazepine-4,7-dione derivatives  $[A_{13}-A_{18}]$  as indicated in scheme (3-7).





The (C.H.N.) elementery microanalysis table (2-5) of bisazo bis -1,3 oxazepines  $[A_{13}-A_{18}]$  showed good agreement between the calculated and found values.

The FT-IR spectrum, figures (3-15) - (3-20) of compounds  $[A_{13}-A_{18}]$  provide good evidence that cycloaddition reactions took place successfully through disappearing the strong band at the general range (1629-1600) cm<sup>-1</sup> which assigned to v (C=N) and appearing one or two bands at frequency relatively higher than that of (C=N) group at (1703 and 1656) cm<sup>-1</sup>,1691cm<sup>-1</sup>,(1716 and 1641) cm<sup>-1</sup>,1701cm<sup>-1</sup>, 1699cm<sup>-1</sup> and 1705 cm<sup>-1</sup> respectively attributed to the stretching vibrations of carbonyl groups (O=C-O) and (O=C-N) inside oxazepine ring respectively.It is important to refer that appearance only oneband for (C=O) groups inside oxazepine with their interpretation were lisited in table (3-3).

| Table (3-3) : FT-IR data of the synthesized bisazobis -1,3-oxazepine-4,7-dione |
|--------------------------------------------------------------------------------|
| derivatives [A <sub>13</sub> -A <sub>18</sub> ]                                |

| Com.            | FT-IR bands                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| no.             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| A <sub>13</sub> | 3236 ( $\upsilon_{O-H}$ ), 3055 ( $\upsilon_{C-H}$ , benzene rings), 2935 ( $\upsilon_{as.C-H,CH^2,cyclohexane}$ ), 2858 ( $\upsilon_{s.C-H,CH^2,cyclohexane}$ ), 1703 ( $\upsilon_{C=O,O=C-O,oxazepine}$ ), 1656 ( $\upsilon_{C=O,O=C-N,oxazepine}$ ), 1591,1523 and 1481 ( $\upsilon_{C=C,benzene rings}$ ),1375( $\delta_{s.C-H, CH^3}$ ), 1313and 1280 ( $\upsilon_{C-N}$ ),1097 ( $\upsilon_{C-O,phenol}$ ), 846, 742 and 704 ( $\delta_{o.o.p.C-H,benzene rings}$ ).                                                                        |
| A <sub>14</sub> | 3498 ( $\upsilon_{O-H}$ ), 3360 ( $\upsilon_{N-H}$ ),3095( $\upsilon_{C-H, benzene rings}$ ),2939 ( $\upsilon_{as\cdot C-H,CH^3}$ ), 2838 ( $\upsilon_{s.C-H,CH^3}$ ), 1691 ( $\upsilon_{C=O,O=C-Oand O=C-N,oxazepine,vib.coupling}$ ), 1572 and 1516 ( $\upsilon_{C=C,benzene rings}$ ), 1392 ( $\delta_{s.C-H, CH^3}$ )1365 and 1267 ( $\upsilon_{C-N}$ ),1118( $\upsilon_{C-O,phenol}$ ), 869,749 and716 ( $\delta_{o.o.p.C-H, benzene rings}$ ).                                                                                              |
| A15             | 3429 ( $\upsilon_{O-H}$ ), 3087 and 3019 ( $\upsilon_{C-H,benzene rings}$ ),2976 and 2920 ( $\upsilon_{as.C-H}$ ,<br>,CH <sup>3</sup> ),2860 ( $\upsilon_{s.C-H,CH^3}$ ), 1716 ( $\upsilon_{C=O,O=C-O,oxazepine}$ ), 1641 ( $\upsilon_{C=O,O=C-O,oxazepine}$ ),1604, 1547 and 1489 ( $\upsilon_{C=C,benzene rings}$ ),1458( $\delta_{as.C-H,CH^3}$ ),1379 ( $\delta_{s.C-H,CH^3}$ ),1344 and 1287( $\upsilon_{C-N}$ ),1105( $\upsilon_{C-O,phenol}$ ), 893,854,825, 810, 767 and 712 ( $\delta_{o.o.p.C-H, benzene rings}$ ).                     |
| A <sub>16</sub> | 3265 and 3203 ( $\upsilon_{O-H}$ ),3063 and 3018( $\upsilon_{C-H}$ , benzene rings), 2952 and 2922( $\upsilon_{as,C-H,CH^3}$ ), 2843 ( $\upsilon_{s,C-H,CH^3}$ ), 1701 ( $\upsilon_{C=O,O=C-Oand O=C-N}$ , oxazepine,vib.coupling), 1622( $\upsilon_{C=C,oxazepine}$ ), 1550,1523,1506 and 1404 ( $\upsilon_{C=C,benzene rings}$ ), 1325 ( $\delta_{s,C-H, CH^3}$ ), 1305and1278 ( $\upsilon_{C-N}$ ),1176( $\upsilon_{C-O,phenol}$ ), 1033 ( $\upsilon_{s,C-O-C,ether}$ ), 887,833,817,803, and 756 ( $\delta_{o.o.p,C-H, benzene rings}$ ).     |
| A <sub>17</sub> | 3275 and 3207 ( $\upsilon_{O-H}$ ),3101and3009( $\upsilon_{C-H}$ , benzene rings),2879 ( $\upsilon_{s.C-H,CH^3}$ ),2854 ( $\upsilon_{C-H,oxazepine}$ ),1699 ( $\upsilon_{C=O,O=C-O}$ and O=C-N,oxazepine,vib.coupling), 1626 ( $\upsilon_{C=C,oxazepine}$ ), 1545 and 1494 ( $\upsilon_{C=C,benzenerings}$ ), 1448 ( $\delta_{as.C-H}$ , CH <sup>3</sup> ), 1325and1269 ( $\upsilon_{C-N}$ ),1153( $\upsilon_{.C-O,phenol}$ ),900,850, 832,759 and 715 ( $\delta_{o.o.p.C-H,benzene rings}$ ).                                                    |
| A <sub>18</sub> | 3510, 3425, 3357, $(\upsilon_{O-H})$ , 3080 and 3014( $\upsilon_{C-H,benzenerings}$ ), 2942( $\upsilon_{as.C-H}$ , CH <sup>3</sup> ), 2870( $\upsilon_{s.C-H,CH^3}$ ), 1705( $\upsilon_{C=O,O=C-Oand O=C-N,oxazepine,vib.coupling}$ ), 1624 ( $\upsilon_{C=C}$ , oxazepine), 1576, 1543, 1516 and 1491 ( $\upsilon_{C=C,benzene rings}$ ), 1392 ( $\delta_{s.C-H, CH^3}$ ), 1315 and 1257 ( $\upsilon_{C-N}$ ), 1107 ( $\upsilon_{C-O,phenol}$ ), 1074( $\upsilon_{C-Br}$ ), 900, 858, 82, 767, 736 and 682( $\delta_{o.o.p.C-H,benzenerings}$ ). |

#### **3.5.** Synthesis of bisimine derivatives [B<sub>1</sub>-B<sub>5</sub>]

A condensation reaction between *o*- Tolidine and equimolar quantity of aromatic aldehydes (2,5-dimethoxybenzaldehyde, 4chlorobenzaldehyde, benzaldehyde, 2- hydroxybenzaldehyde and 4-*N*, *N*- dimethylaminobenzaldehyde ) respectively in presense of glacial acetic acid as catalyst in absolute ethanol afforded bisimine derivatives [B<sub>1</sub>-B<sub>5</sub>] as indicated in scheme (3-8).



#### Scheme (3-8) : Synthesis of bisiminederivatives [B1- B5]

FT-IR spectrum, figures (3-21) - (3-25) of all synthesized bisimine derivatives  $[B_1-B_5]$  illustrate good evidence that the condensation reactions happened successfully by disappearing the sharp bands at (3468,3410) cm<sup>-1</sup> and (3373,3338) cm<sup>-1</sup>which attributed to the asymmetric and symmetric stretching vibrations of the two amino (-NH<sub>2</sub>) groups in *o*-tolidine,also disappearing the sharp and strong band at 1624cm<sup>-1</sup> due to the scissoring bending vibration of (-NH<sub>2</sub>) groups and appearing sharp and medium-strong band at lower frequencies at the general range (1627-1593) cm<sup>-1</sup> assigned to the stretching vibration of imine (C=N) group<sup>(101)</sup>. Other data of functional groups were shown in table (3-4).

Table (3-4): FT-IR data of the synthesized bisimine derivatives  $[B_1-B_5]$ 

| Com.                  | FT-IR bands                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|-----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| no.                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>B</b> 1            | 3055 and 3007( $\upsilon_{C-H,benzene rings}$ ), 2949 and 2916 ( $\upsilon_{as.C-H,CH^3}$ ),2833<br>( $\upsilon_{s.C-H,CH^3}$ ),1620 ( $\upsilon_{C=N}$ ),1595 and1494 ( $\upsilon_{C=C,benzene rings}$ ),1456<br>( $\delta_{as.C-H,CH^3}$ ),1369( $\delta_{s.C-H, CH^3}$ ),1301 and 1267 ( $\upsilon_{C-N}$ ),1217( $\upsilon_{as.C-D-C,ether}$ ),1039 ( $\upsilon_{s.C-O-C,ether}$ ), 866,808 and 705 ( $\delta_{o.o.p.C-H,benzene rings}$ ). |
| $\mathbf{B}_2$        | 3061 and 3022( $\upsilon_{C-H,benzene rings}$ ),2972 ( $\upsilon_{as.C-H,CH^3}$ ), 2874 ( $\upsilon_{s.C-H}$ , <sub>CH<sup>3</sup></sub> ),1622 ( $\upsilon_{C=N}$ ),1593,1562 and1485 ( $\upsilon_{C=C,benzenerings}$ ),1444 ( $\delta_{as.C-H,CH^3}$ ),1361( $\delta_{s.C-H,CH^3}$ ), 1286 ( $\upsilon_{C-N}$ ),1087( $\upsilon_{C-CI}$ ), 877,825and 730 ( $\upsilon_{C-H 0.0.p.}$ , benzene rings).                                         |
| <b>B</b> <sub>3</sub> | 3059 and 3024( $\upsilon_{C-H,benzene rings}$ ),2984 ( $\upsilon_{as.C-H,CH^3}$ ), 2918 ( $\upsilon_{s.C-H}$ , <sub>CH<sup>3</sup></sub> ),1627 ( $\upsilon_{C=N}$ ),1608,1572 and1483 ( $\upsilon_{C=C,benzene rings}$ ),1448( $\delta_{as.C-H,CH^3}$ ),1371( $\delta_{s.C-H,CH^3}$ ), 1307( $\upsilon_{C-N}$ ), 877,812, 758,708 and 690 ( $\delta_{o.o.p.C-Hbenzene rings}$ ).                                                               |
| <b>B</b> 4            | 3421( $v_{O-H}$ ), 3055 and 3032( $v_{C-H,benzene rings}$ ), 2985 and 2939 ( $v_{as.}$<br><sub>C-H,CH<sup>3</sup></sub> ), 2904 ( $v_{s.C-H,CH^3}$ ),2715 ( $v_{C-H,imine group}$ ),1612 ( $v_{C=N}$ ),1566<br>and 1483 ( $v_{C=C,benzene rings}$ ), 1454 ( $\delta_{as.C-H,CH^3}$ ),1367( $\delta_{s.C-H,CH^3}$ ),1301and1278 ( $v_{C-N}$ ),1182( $v_{C-O, phenol}$ ), 890,868, 853,808 and<br>750 ( $\delta_{o.o.p.C-H,benzene rings}$ ).     |
| <b>B</b> 5            | 3049 and 3012( $\upsilon_{C-H,benzene rings}$ ), 2983 and 2945( $\upsilon_{as.C-H,CH^3}$ ), 2897<br>and 2862 ( $\upsilon_{s.C-H,CH^3}$ ), 2810 ( $\upsilon_{C-H,imine group}$ ),1593 ( $\upsilon_{C=N}$ ),1525<br>and1479 ( $\upsilon_{C=C,benzene rings}$ ),1437 ( $\delta_{as.C-H,CH^3}$ ),1361( $\delta_{s.C-H, CH^3}$ ),1315<br>and 1228( $\upsilon_{C-N}$ ), 877,815and 715( $\delta_{o.o.p.C-H,benzenerings}$ ).                          |

#### 3.6. Synthesis of bis -1,3-oxazepine-4,7-dione derivatives[B<sub>6</sub>-B<sub>10</sub>]

A (5+2 - 7) cycloaddition reaction of equimolar amount of phathalic anhydride and the synthesized bisimines  $[B_1-B_5]$  was used for synthesis a series of bis-1,2-disubstituted-1,3-oxazepine-4,7-dione derivatives  $[B_6-B_{10}]$  as shown in scheme (3-9).



Scheme (3-9) : Synthesis of bis-1,3-oxazapine-4,7-dionederivatives [B<sub>6</sub>-B<sub>10</sub>]

The (C.H.N.) elementary microanalysis, table (2-9) of the synthesized compounds  $[B_6-B_{10}]$  showed good agreement between the caculated and found values.

The FT-IR spectrum, figures (3-26) - (3-30) of compounds  $[B_6-B_{10}]$  illustrate good evidence that the cycloaddition reactions took place successfully by disappearing the band at the general range (1627-1593) cm<sup>-1</sup> which attributed to v (C=N) and appearing one or two bands at (1701,1658) cm<sup>-1</sup>, (1699,1654) cm<sup>-1</sup>, (1695,1637) cm<sup>-1</sup>,1693 cm<sup>-1</sup>and (1697,1660) cm<sup>-1</sup>, the first one assigned to stretching vibration of (C=O) group in (O=C-O) inside oxazepine ring while the second attributed to the streching vibration of (C=O)<sup>(102)</sup> group in (O=C-N) inside oxazepine ring. Other characteristic bands with their interpretation were listed in table (3-5).

Table (3-5): FT-IR data of the synthesized bis -1,3-oxazepine-4,7-dione derivatives  $[B_6-B_{10}]$ 

| Com.                   | FT-IR bands                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| no.                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>B</b> <sub>6</sub>  | 3026( $\upsilon_{C-H,benzene rings}$ ), 2897 ( $\upsilon_{as.C-H,CH^3}$ ), 2835 ( $\upsilon_{s.C-H,CH^3}$ ), 1701 ( $\upsilon_{C=O,O=C-O,oxazepine}$ ), 1658 ( $\upsilon_{C=O,O=C-N,oxazepine}$ ), 1589,1519 and 1496 ( $\upsilon_{C=C,benzene rings}$ ), 1450 ( $\delta_{as.C-H, CH^3}$ ), 1390 ( $\delta_{s.C-H, CH^3}$ ), 1286 ( $\upsilon_{C-N}$ ), 1222 ( $\upsilon_{as.C-O-C,ether}$ ), 1074 ( $\upsilon_{s.C-O-C}$ , oxazepine), 1039( $\upsilon_{s.C-O-C,ether}$ ), 914,808,742 and 705 ( $\delta_{o.o.p.C-H, benzene rings}$ ). |
| <b>B</b> 7             | 3026 ( $\upsilon_{C-H,benzene rings}$ ),2928 ( $\upsilon_{as.C-H,CH^3}$ ), 2893 ( $\upsilon_{s.C-H,CH^3}$ ),1699 ( $\upsilon_{C=O,O=C-O,oxazepine}$ ), 1654 ( $\upsilon_{C=O,O=C-N,oxazepine}$ ), 1589, 1518 and 1491( $\upsilon_{C=C,benzene rings}$ ), 1448 ( $\delta_{as.C-H, CH^3}$ ),1310 and1290 ( $\upsilon_{C-N}$ ), 1080 ( $\upsilon_{C-Cl}$ ), 912, 879, 808, 740,700 and 680 ( $\delta_{o.o.p.C-H, benzene rings}$ ).                                                                                                         |
| <b>B</b> 8             | 3167 and 3030 ( $\upsilon_{C-H,benzene rings}$ ), 2868 <sub>br</sub> ( $\upsilon_{as. and s.C-H,CH^3,interacted}$ ),<br>1695 ( $\upsilon_{C=O,O=C-O,oxazepine}$ ), 1637( $\upsilon_{C=O,O=C-N,oxazepine}$ ), 1587, 1529 and<br>1491 ( $\upsilon_{C=C,benzene rings}$ ), 1446 ( $\delta_{as.C-H,CH^3}$ ), 1361( $\delta_{s.C-H, CH^3}$ ), 1311 and<br>1276 ( $\upsilon_{C-N}$ ), 1072 ( $\upsilon_{as.C-O,oxazepine}$ ), 910, 877, 806, 761 and<br>698( $\delta_{o.o.p.C-H,benzene rings}$ ).                                             |
| <b>B</b> 9             | 3437 ( $\upsilon_{O-H}$ ), 3086 and 3022 ( $\upsilon_{C-H}$ , benzene rings), 2989 ( $\upsilon_{as. C-H,CH^3}$ ),<br>2885 ( $\upsilon_{s.C-H,CH^3}$ ), 1693 ( $\upsilon_{C=O,O=C-O \text{ and } O=C-N, \text{ oxazepine,vib.coupling}$ ), 1587,<br>1518 and 1500 ( $\upsilon_{C=C,\text{benzene rings}}$ ), 1446 ( $\delta_{as.C-H, CH^3}$ ), 1371 ( $\delta_{s.C-H, CH^3}$ )<br>,1285 and 1278 ( $\upsilon_{C-N}$ ), 1072 ( $\upsilon_{as.C-O,\text{oxazepine}}$ ), 910,794,738,700<br>and 682 ( $\delta_{o.o.p.C-H}$ , benzene rings). |
| <b>B</b> <sub>10</sub> | 3103 and 3024 ( $\upsilon_{C-H,benzene rings}$ ), 2980 and 2899 ( $\upsilon_{as.C-H,CH3}$ ), 2862<br>and 2812 ( $\delta_{s.C-H,CH3}$ ), 1697 ( $\upsilon_{C=0,O=C-Ooxazepine}$ ), 1660 ( $\upsilon_{C=0,O=C-N}$<br>,oxazepine),1589,1545, 1525 and 1481( $\upsilon_{C=C,benzene rings}$ ),1437( $\delta_{as.C-H}$ ,<br>CH3), 1361( $\delta_{s.C-H,CH3}$ ), 1313,1278 and 1232 ( $\upsilon_{C-N}$ ), 879, 815 and<br>740 ( $\delta_{o.o.p.C-H,benzene rings}$ ).                                                                          |

### 3.7. Synthesis of bis -1,3-oxazepine-4,7-dione derivatives [B<sub>11</sub>-B<sub>15</sub>]

The synthesized bisimines  $[B_1-B_5]$  were also introduced in  $(5+2 \rightarrow 7)$  cycloaddition reaction with maleic anhydride as five-membered component to produce a series of bis-1,2-disubstituted-1,3-oxazepine-4,7-dione derivatives  $[B_{11}-B_{15}]$  as indicated in scheme (3-10).





The (C.H.N.) elementary microanalysis, table (2-9) of the synthesized compounds  $[B_{11}-B_{15}]$  showed closeness between the calculated and found values.

The FT-IR spectrum, figures (3-31) - (3-35) of compounds  $[B_{11}-B_{15}]$  provide good evidence that cycloaddition reactions happened successfully through disappearing the band around (1627-1593) cm<sup>-1</sup> which assigned to the stretching vibrations of (C=N) groups and appearing strong band at (1712,1705,1712,1710 and 1710) cm<sup>-1</sup> respectively belong to v (C=O) in (O=C-O) and (O=C-N) groups inside oxazepine ring due to the vibration coubling. Moreover, the spectra of compounds  $[B_{11}-B_{14}]$  appeared medium band at (1629,1627,1623 and 1622) cm<sup>-1</sup> respectively which attributed to v (C=C) inside oxazepine ring. Other caracteristic bands with their interpretation were summarized in table (3-6).

Table (3-6): FT-IR data of the synthesized bis -1,3-oxazepine-4,7-dione derivatives  $[B_{11}-B_{15}]$ 

| Com.                   | FT-IR bands                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| no.                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| B11                    | 3051and 3001( $\upsilon_{C-H,benzene rings}$ ), 2986 ( $\upsilon_{as.C-H,CH^3}$ ), 2841 ( $\upsilon_{s.C-H,CH^3}$ ), 1712 ( $\upsilon_{C=O,O=C-O \text{ and } O=C-N,oxazepine,vib.coupling}$ ), 1629 ( $\upsilon_{C=C,oxazepine}$ ), 1573 ,1529 and 1492 ( $\upsilon_{C=C,benzene rings}$ ), 1451( $\delta_{as.C-H,CH^3}$ ), 1359 ( $\delta_{s.C-H,CH^3}$ ), 1305 and 1278 ( $\upsilon_{C-N}$ ), 1219( $\upsilon_{as.C-O-C,ether}$ ), 848, 813and 716( $\delta_{o.o.p.C-H,benzene rings}$ ).                           |
| <b>B</b> <sub>12</sub> | 3041( $\upsilon_{C-H,benzene rings}$ ),2980 ( $\upsilon_{as.C-H,CH^3}$ ),2861 ( $\upsilon_{s.C-H,CH^3}$ ),1705 ( $\upsilon_{C=0,O=C-O \text{ and } O=C-N,oxazepine,vib.coupling}$ ),1627 ( $\upsilon_{C=C,oxazepine}$ ), 1587,1566 ,1533 and 1489 ( $\upsilon_{C=C,benzene rings}$ ),1450( $\delta_{as.C-H, CH^3}$ ),1355 ( $\delta_{s.C-H, CH^3}$ ),1292 ( $\upsilon_{C-N}$ ),1091( $\upsilon_{C-CI}$ ), 892, 852 and 825( $\delta_{o.o.p.C-H, benzene rings}$ ).                                                     |
| B <sub>13</sub>        | 3049 ( $\upsilon_{C-H,benzene rings}$ ), 2929 ( $\upsilon_{as.C-H,CH^3}$ ), 2860 ( $\upsilon_{s.C-H,CH^3}$ ), 1710 ( $\upsilon_{C=O,O=C-O}$ and O=C-N,oxazepine,vib.coupling),1623 ( $\upsilon_{C=C,oxazepine}$ ), 1554, 1533 and 1492 ( $\upsilon_{C=C,benzene rings}$ ), 1301 ( $\upsilon_{C-N}$ ),889, 850, 821, 752 and 690 ( $\delta_{o.o.p.C-H,benzene rings}$ ).                                                                                                                                                |
| <b>B</b> 14            | 3392( $\upsilon_{O-H}$ ), 3051( $\upsilon_{C-H,benzene rings}$ ), 2985 ( $\upsilon_{as.C-H,CH^3}$ ),2874 ( $\upsilon_{s.C-H}$ ,CH <sup>3</sup> ),1710 ( $\upsilon_{C=O,O=C-O \text{ and } O=C-N,oxazepine,vib.coupling}$ ),1622 ( $\upsilon_{C=C,oxazepine}$ ), 1575, 1529 and 1489 ( $\upsilon_{C=C,benzene rings}$ ),1434( $\delta_{as.C-H, CH^3}$ ),1381 ( $\delta_{s.C-H, CH^3}$ ),1271 ( $\upsilon_{C-N}$ ),1152 ( $\upsilon_{C-O,phenol}$ ), 856,817,771,750,711 and 682 ( $\delta_{o.o.p.C-H,benzene rings}$ ). |
| <b>B</b> <sub>15</sub> | 3039( $\upsilon_{C-H, benzene rings}$ ), 2982 and 2939 ( $\upsilon_{as.C-H,CH^3}$ ), 2899 ( $\upsilon_{s.C-H}$ , ,CH <sup>3</sup> ), 1710 ( $\upsilon_{C=O,O=C-O \text{ and } O=C-N,oxazepine,vib.coupling}$ ),1589 ( $\upsilon_{C=C,oxazepine}$ ),1535 and 1489 ( $\upsilon_{C=C,benzene rings}$ ),1448 ( $\delta_{as.C-H, CH^3}$ ), 1392 ( $\delta_{C-H, N(CH^3)^2}$ ),1359 ( $\delta_{s.C-H, CH^3}$ ),1307 ( $\upsilon_{C-N}$ ), 848, 817,781 and 723 ( $\delta_{o.o.p.C-H, benzene rings}$ ).                      |

#### <sup>1</sup>H NMR spectra

<sup>1</sup>H NMR spectra, figure (3-36), ( $\mu$ H<sub>Z</sub>, DMSO-d<sub>6</sub>) of compound [A<sub>7</sub>] showed the following signals in  $\delta$  (ppm) : The signal at (1.061-1.344) ppm attributed to protons (a) in cyclohexane rings, (quintet,4H,4×Ha). The signal at (1.401-1.591) ppm belong to protons (b) in cyclohexane rings, (quintet,8H,8×Hb). The signal at 1.70 ppm due to protons (c) in cyclohexane rings, (quartet,8H,8×Hc). The signal at 1.811 ppm assigned to protons (d) in cyclohexane rings, (quintet,2H,2×Hd).The signal at (2.442-2.569) ppm attributed to DMSO solvent. The singlet signal at (3.675-3.690) ppm due to H<sub>2</sub>O in DMSO.The signals of aromatic protons and protons of (C-H) groups inside oxazepine rings appeared at the range (6.850-9.140) ppm.The signals of phenolic hydroxy groups protons appeared at 10.447 ppm as sharp, (11.382-11.993), 14.114 and 14.665 ppm as broad, (2H,2×H-O).

<sup>1</sup>H NMR spectra, figure (3-37), ( $\mu$ H<sub>z</sub>, DMSO-d<sub>6</sub>) of compound [A<sub>8</sub>] showed the following signals at  $\delta$  (ppm): The signal at (2.403-2.569) ppm attributed to DMSO solvent. The singlet signal at 2.735 ppm assigned to methyl groups protons, (6H,2×CH<sub>3</sub>). The broad signal at (3.228-3.496) ppm attributed to H<sub>2</sub>O in DMSO. The two signals at (4.221-4.293) ppm and 4.526 ppm belong to protons of (N-H) groups, (2H,2×N-H). The signals of aromatic protons <sup>(101)</sup> and (C-H) protonsof oxazepine rings appeared at the range (6.769-8.257) ppm. The two signals at 10.627 ppm and 11.143 ppm assigned to protons of phenolic hydroxy groups, (2H,2×H-O).

<sup>1</sup>H NMR spectra, figure (3-38), ( $\mu$ H<sub>Z</sub>, DMSO-d<sub>6</sub>) of compound [A<sub>9</sub>] showed the following signals at  $\delta$  (ppm): The signal at (2.437-2.570) ppm due to DMSO solvent. The singlet signal at 2.636 ppm attributed to methyl group protons (a), (s,3H, 3×Ha). The signal at (2.705- 2.728) ppm assigned to methyl group protons (b) (s,3H, 3×Hb).The signal at (2.771- 2.796) ppm attributed to methyl group protons (c), (s, 6H , 6×Hc).The broad signal at (3.145-3.625) ppm due to the H<sub>2</sub>O in DMSO solvent. The signals of aromatic protons and (C-H) protons of oxazepine rings<sup>(104)</sup> appeared at the range (7.157-7.880) ppm. The signal of phenolic hydroxy groups protons appeared asbroad at the range (12.894-13.482) ppm , (2H,2×O-H).

<sup>1</sup>H NMR spectra, figure (3-39), ( $\mu$ H<sub>z</sub>, DMSO-d<sub>6</sub>) of compound [A<sub>10</sub>] showed the following signals at  $\delta$  (ppm): The signal at (2.437-2.570) ppm due to DMSO solvent. The two signals at (2.722- 2.728) ppm and (2.771- 2.795) ppm attributed to methyl groups protons, (6H, 2×CH<sub>3</sub>) .The signal of H<sub>2</sub>O in DMSO solvent<sup>(104)</sup> appeared as broad at (3.091-3.547) ppm. The singlet signals at 3.733 ppm and 3.819 ppm attributed to methoxy groups protons, (6H, 2×CH<sub>3</sub>O). The signals of aromatic protons and (C-H) protons of oxazepine rings appeared at the range (6.918-9.179) ppm. The broad signal at the range (12.939-13.334) ppm assigned to the phenolic hydroxy groups protons, (2H,2×O-H).

<sup>1</sup>H NMR spectra, figure (3-40), ( $\mu$ H<sub>Z</sub>, DMSO-d<sub>6</sub>) of compound [A<sub>11</sub>] showed the following signals at  $\delta$  (ppm): The signal at (2.436-2.569) ppm due to DMSO solvent. The singlet signal at 2.787 ppm assigned to methyl groups protons, (6H, 2×CH<sub>3</sub>) .The signal of H<sub>2</sub>O in DMSO solvent appeared at (3.274- 3.404) ppm. The signals of aromatic protons and (C-H)

protons inside oxazepine rings appeared at the range (7.044 - 9.189) ppm. The two signals at 10.329 ppm and 10.386 ppm assigned to phenolic hydroxy groups protons,  $(2H,2\times O-H)$ .

<sup>1</sup>H NMR spectra, figure (3-41), ( $\mu$ H<sub>Z</sub>, DMSO-d<sub>6</sub>) of compound [A<sub>13</sub>] showed the following signals at  $\delta$  (ppm) : The signal at (1.021-1.352) ppm attributed to protons (a) in cyclohexane rings, (quintet,4H,4×Ha). The signal at (1.395-1.582) ppm belong to protons (b) in cyclohexane rings, (quartet,8H,8×Hb). The signal at (1.684-1.800) ppm attributed to protons (c) in cyclohexane rings, (quartet,8H,8×Hc). The signal at 1.885 ppm due to protons (d) in cyclohexane rings, (quintet, 2H, 2×Hd). The signal of DMSO solvent appeared at (2.439-2.570) ppm. The two signals at (2.713-2.736) ppm and 2.878 ppm assigned to methyl groups protons, (6H,2×CH<sub>3</sub>). The broad signal at (3.338-3.613) ppm belong to H<sub>2</sub>O in DMSO solvent. The spectrum illustrates good evidence that the cycloaddition reaction happened successfully and formed the desired product, oxazepine derivative  $[A_{13}]$ , by appearing two doublet signals at (6.220-6.261) ppm and (6.446-6.488) ppm assigned to olefinic (C-H) protons (e and f) respectively inside oxazepine rings. The signal at 6.088 ppm may be due to olefine (C-H) proton (e) in *cis* position to (C=O) group, so its signal is shifted towards high field region. The signals of aromatic protons and protons of (C-H) inside oxazepine rings appeared at the range (6.848-9.202) ppm. The two signals at 10.374 ppm and 11.625 ppm belong to protons of phenolic hydroxy groups,  $(2H, 2 \times H-O)$ .

<sup>1</sup>H NMR spectra, figure (3-42), ( $\mu$ H<sub>z</sub>, DMSO-d<sub>6</sub>) of compound [A<sub>14</sub>] showed the following signals at  $\delta$  (ppm) : The signal at (2.404 - 2.575) ppm attributed to DMSO solvent. The signal at (2.729- 2.774) ppm assigned to methyl groups protons, (6H , 2×CH<sub>3</sub>). The broad signal at (3.120 -3.501) ppm attributed to H<sub>2</sub>O in DMSO. The signal of (N-H) protons may be interacted with the broad signal of H<sub>2</sub>O in DMSO.The spectrum provides good evidence that the cycloaddition reaction proceeded successfully and give the desired oxazepine derivative [A<sub>14</sub>] by appearing two signals at 5.973 ppm and 6.106 ppm attributed to (C-H) protons (a), (2H, 2×Ha) while the second signal belong to (C-H) protons (b), (2H, 2×Hb). The signals of aromatic protons and (C-H) protons of oxazepine rings appeared at the range (6.773 -8.617) ppm.The two signals at 10.594 ppm and 11.123 ppm assigned to the phenolic hydroxy groups protons , (2H, 2×H-O).

<sup>1</sup>H NMR spectra, figure (3-43), ( $\mu$ H<sub>z</sub>, DMSO-d<sub>6</sub>) of compound [A<sub>15</sub>] showed the following signals at  $\delta$  (ppm): The signal at (2.430 -2.575) ppm due to DMSO solvent . The signal at (2.723 -2.735) ppm attributed to methyl groups protons (a), (6H, 6×Ha). The signal at (2.770 -2.793) ppm attributed to methyl groups protons (b), (6H, 6×Hb). The signal of H<sub>2</sub>O in DMSO solvent appeared at the range (3.136-3.921) ppm. The two signals at 6.178 ppm and 6.311ppm assigned to olefinic (C-H) protons in structure of oxazepine rings which provide good evidence that the cycloaddition reaction proceeded successfully and yielded the desired oxazepine derivative [A<sub>15</sub>]. The signals at the range (7.155- 9.148) ppm attributed to aromatic protons and (C-H) protons of oxazepine rings. The singlet signal at 10.391 ppm belong to the phenolic hydroxy groups protons,  $(2H, 2 \times H-O)$ .

<sup>1</sup>H NMR spectra, figure (3-44), (µH<sub>z</sub>, DMSO-d<sub>6</sub>) of compound  $[A_{16}]$  showed the following signals at  $\delta$  (ppm): The signal at (2.437 -2.570) ppm attributed to DMSO solvent. The singlet signal at (2.765 -2.785) ppm assigned to methyl groups protons,  $(6H, 2 \times CH_3)$ . The signal at the range (3.308-3.665) ppm belong to H<sub>2</sub>O in DMSO solvent. The two signals at (3.798-3.813) ppm and (3.880-3.969) ppm belong to methoxy groups protons, (6H,  $6 \times H_3C$ -O). The spectrum illustrates good evidence that the cycloaddition reaction happened successfully and formed oxazepine derivative  $[A_{16}]$  by appearing two signals for olefinic (C-H) protons inside oxazepine rings, the first signal appeared as triplet at (6.211- 6.282) ppm attributed to olefinic (C-H) protons (a), (2H  $,2\times$ Ha) while the second signal appeared at the range (6.382- 6.515) ppm belong to olefinic (C-H) protons (b),  $(2H,2\times Hb)$ . The signals of aromatic protons and (C-H) protons of oxazepine rings appeared at the range (6.833-9.165) ppm. The two signals at (10.388 -10.479) ppm and at (13.356-13.555) ppm belong to the phenolic hydroxy groups protons, (2H, 2×O-H).

<sup>1</sup>H NMR spectra, figure (3-45), ( $\mu$ H<sub>z</sub>, DMSO-d<sub>6</sub>) of compound [A<sub>17</sub>] showed the following signals at  $\delta$  (ppm): The signal at (2.436 -2.570) ppm belong to DMSO solvent. The signal at (2.739 -2.780) ppm assigned to methyl groups protons, (6H, 2×CH<sub>3</sub>). The broad signal at (3.307-3.496) ppm attributed to H<sub>2</sub>O in DMSO solvent. The signals at the range (6.196 -6.498) ppm attributed to olefinic (C-H) protons inside oxazepine rings ,(4H, 4×C-H) which provide good evidence that the cycloaddition

reaction happened successfully and yielded the desired oxazepine derivative [A<sub>17</sub>]. The signals of aromatic protons and (C-H) protons of oxazepine rings appeared at the range (7.065 -9.180) ppm .The two signals at 10.395 ppm and 11.524 ppm assigned to the phenolic hydroxy groups protons, (2H,  $2\times$ H-O).

<sup>1</sup>H NMR spectra, figure (3-46), ( $\mu$ H<sub>z</sub>, DMSO-d<sub>6</sub>) of compound [B<sub>7</sub>] showed the following signals at  $\delta$  (ppm): The singlet signals at 2.154 ppm and 2.355 ppm attributed to methyl groups protons, (6H, 2×CH<sub>3</sub>). The singlet signal at 2.505 ppm belong to DMSO solvent. The singlet signal at 3.369 ppm due to H<sub>2</sub>O in DMSO solvent. The signals at the range (6.713 - 8.617) ppm attributed to aromatic protons and (C-H) protons of oxazepine rings.

<sup>1</sup>H NMR spectra, figure (3-47), ( $\mu$ H<sub>z</sub>, DMSO-d<sub>6</sub>) of compound [B<sub>8</sub>] showed the following signals at  $\delta$  (ppm): The signals at 2.154 ppm and (2.305 -2.417) ppm attributed to methyl groups protons, (6H, 2×CH<sub>3</sub>). The singlet signal at 2.518 ppm due to DMSO solvent. The singlet signal at 3.407 ppm belong to H<sub>2</sub>O in DMSO solvent. The signals of aromatic protons and protons of (C-H) inside oxazepine rings appeared at the range (6.738 -8.592) ppm.

<sup>1</sup>H NMR spectra, figure (3-48), ( $\mu$ H<sub>Z</sub>, DMSO-d<sub>6</sub>) of compound [B<sub>11</sub>] showed the following signals at  $\delta$  (ppm) : The signals at (2.160 - 2.371) ppm attributed to methyl groups protons, (6H, 2×CH<sub>3</sub>) . The signal at (2.504 -2.571) ppm belong to DMSO solvent. The signal of H<sub>2</sub>O in DMSO solvent appeared at 3.391 ppm.The two signals at (3.759 -3.789) ppm and (3.856 -3.880) ppm assigned to methoxy groups protons, (12H, 4×O-CH<sub>3</sub>). The spectrum illustrates good evidence that the cycloaddition

reaction happened successfully and formed the desired oxazepine derivative  $[B_{11}]$  by appearing two signals at (6.239 -6.342) ppm and (6.595 -6.632) ppm assigned to olefinic (C-H) protons (a), (2H , 2×Ha) and olefinic (C-H) protons (b), (2H, 2×Hb) respectively inside oxazepine rings .The signals of aromatic protons and (C-H) protons inside oxazepine rings appeared at the range (7.132 -8.768) ppm.

<sup>1</sup>H NMR spectra, figure (3-49) , ( $\mu$ H<sub>z</sub>, DMSO-d<sub>6</sub>) of compound [B<sub>12</sub>] showed the following signals at  $\delta$  (ppm) : The signals at ( 2.260 - 2.283) ppm and (2.430 -2.437) ppm attributed to methyl groups protons, (6H,2×CH<sub>3</sub>) . The signal of DMSO solvent appeared at (2.443 -2.575) ppm. The broad signal at (3.338 -3.616) ppm due to H<sub>2</sub>O in DMSO solvent. The spectrum provides good evidence that the cycloaddition reaction proceeded successfully and gave the desired oxazepine derivative [B<sub>12</sub>] by appearing signals of olefinic (C-H) protons at (6.156 - 6.407) ppm for protons (a), (2H, 2×Ha) and (6.597 -6.698) ppm for protons (b), (2H, 2×Hb). The signals of aromatic protons and (C-H) protons inside oxazepine rings appeared at the range (7.169 -8.606) ppm.

<sup>1</sup>H NMR spectra, figure (3-50) , ( $\mu$ H<sub>z</sub>, DMSO-d<sub>6</sub>) of compound [B<sub>13</sub>] showed the following signals at  $\delta$  (ppm) : The signals at (2.155 - 2.390) ppm attributed to methyl groups protons, (6H, 2×CH<sub>3</sub>) .The singlet signal at 2.510 ppm belong to DMSO solvent. The broad signal at 3.398 ppm due to H<sub>2</sub>O in DMSO solvent. The spectrum showed appearance of two signals at (6.238 -6.346) ppm for olefinic (C-H) protons (a), (2H, 2×Ha) and (6.598 -6.634) ppm for olefinic (C-H) protons (b), (2H, 2×Hb) which is considered good evidence that the

cycloaddition reaction took place successfully and yielded the desired oxazepine derivative  $[B_{13}]$ . The signals of aromatic protons and (C-H) protons inside oxazepine rings appeared at the range (7.511-8.591) ppm.

<sup>1</sup>H NMR spectra, figure (3-51), ( $\mu$ H<sub>Z</sub>, DMSO-d<sub>6</sub>) of compound [B<sub>15</sub>] showed the following signals at  $\delta$  (ppm): The signals at ( 2.167 - 2.392) ppm assigned to methyl groups protons (a), (6H , 2×CH<sub>3</sub>) .The singlet signal at 2.505 ppm belong to DMSO solvent. The singlet signal at 3.069 ppm attributed to methyl groups protons (b), (12H , 4×H<sub>3</sub>C-N) . The broad signal at 3.469 ppm due to H<sub>2</sub>O in DMSO solvent.The spectrum illustrates good evidence that the cycloaddition reaction happened successfully and produced the desired oxazepine derivative [B<sub>15</sub>] by appearing signals of olefinic (C-H) protons at (6.225 -6.350) ppm for olefinic protons (c) ,(2H, 2×Hc) and 6.626 ppm for protons (d) , (2H, 2×Hd). The signals of aromatic protons and (C-H) protons inside oxazepine rings appeared at the range (6.826-8.454) ppm.



Figure (3-1) : FT-IR spectrum of *o*-toludine



Figure (3-2) : FT-IR spectrum of compound [A]



Figure (3-3) : FT-IR spectrum of compound [A<sub>1</sub>]



Figure (3-4) : FT-IR spectrum compound [A<sub>2</sub>]



Figure (3-5) : FT-IR spectrum of compound [A<sub>3</sub>]



Figure (3-6) : FT-IR spectrum of compound [A<sub>4</sub>]



Figure (3-7) : FT-IR spectrum of compound [A<sub>5</sub>]



Figure (3-8) : FT-IR spectrum of compound [A<sub>6</sub>]



Figure (3-9) : FT-IR spectrum of compound [A<sub>7</sub>]



Figure (3-10) : FT-IR spectrum of compound [A<sub>8</sub>]



Figure (3-11) : FT-IR spectrum of compound [A<sub>9</sub>]


Figure (3-12) : FT-IR spectrum of compound [A<sub>10</sub>]



Figure (3-13) : FT-IR spectrum of compound [A<sub>11</sub>]



Figure (3-14) : FT-IR spectrum of compound [A<sub>12</sub>]



Figure (3-15) : FT-IR spectrum of compound [A<sub>13</sub>]



Figure (3-16) : FT-IR spectrum of compound [A<sub>14</sub>]



Figure (3-17) : FT-IR spectrum of compound [A<sub>15</sub>]



Figure (3-18) : FT-IR spectrum of compound [A<sub>16</sub>]



Figure (3-19) : FT-IR spectrum of compound [A<sub>17</sub>]



Figure (3-20) : FT-IR spectrum of compound [A<sub>18</sub>]



Figure (3-21) : FT-IR spectrum of compound [B<sub>1</sub>]



Figure (3-22) : FT-IR spectrum of compound [B<sub>2</sub>]



Figure (3-23) : FT-IR spectrum of compound [B<sub>3</sub>]



Figure (3-24) : FT-IR spectrum of compound [B<sub>4</sub>]



Figure (3-25) : FT-IR spectrum of compound [B<sub>5</sub>]



Figure (3-26) : FT-IR spectrum of compound [B<sub>6</sub>]



Figure (3-27) : FT-IR spectrum of compound [B<sub>7</sub>]



Figure (3-28) : FT-IR sbectrum of compound [B<sub>8</sub>]

## Chapter Three



Figure (3-29) : FT-IR spectrum of compound [B<sub>9</sub>]



Figure (3-30) : FT-IR spectrum of compound [B<sub>10</sub>]



Figure (3-31) :FT-IR spectrum of compound [B<sub>11</sub>]



Figure (3-32) :FT-IR spectrum of compound [B<sub>12</sub>]



Figure (3-33) : FT-IR spectrum of compound [B<sub>13</sub>]



Figure (3-34) : FT-IR spectrum of compound [B<sub>14</sub>]



Figure (3-35) : FT-IR spectrum of compound [B<sub>15</sub>]



Figure (3-36) : <sup>1</sup>H NMR spectrum of compound [A<sub>7</sub>]



Figure (3-37) : <sup>1</sup>H NMR spectrum of compound [A<sub>8</sub>]



Figure (3-38) : <sup>1</sup>H NMR spectrum of compound [A<sub>9</sub>]



Figure (3-39) : <sup>1</sup>H NMR spectrum of compound [A<sub>10</sub>]



Figure (3-40) : <sup>1</sup>H NMR spectrum of compound [A<sub>11</sub>]



Figure (3-41) : <sup>1</sup>H NMR spectrum of compound [A<sub>13</sub>]



Figure (3-42) : <sup>1</sup>H NMR spectrum of compound [A<sub>14</sub>]



Figure (3-43) : <sup>1</sup>H NMR spectrum of compound [A<sub>15</sub>]



Figure (3-44) : <sup>1</sup>H NMR spectrum of compound [A<sub>16</sub>]



Figure (3-45) : <sup>1</sup>H NMR spectrum of compound [A<sub>17</sub>]



Figure (3-46) : <sup>1</sup>H NMR spectrum of compound [B<sub>7</sub>]



Figure (3-47) : <sup>1</sup>H NMR spectrum of compound [B<sub>8</sub>]







Figure (3-49) : <sup>1</sup>H NMR spectrum of compound [B<sub>12</sub>]

Chapter Three



Figure (3-50) : <sup>1</sup>H NMR spectrum of compound [B<sub>13</sub>]



Figure (3-51) : <sup>1</sup>H NMR spectrum of compound [B<sub>15</sub>]

## Conclusions

- The Formation of azoimine derivatives [A<sub>1</sub>-A<sub>6</sub>] by the reaction of bis-azoaldehyde derivative [A] with primary amines is more difficult than that of direct reaction between *o*- tolidine and aldehydes, the reason may be due to the intramolecular hydrogen bonding between carbonyl group and *o*- hydroxy group which leads to form a six- membered ring gives higher stabilization for carbonyl group, so the rate of reaction will be decreased.
- 2. The Reaction rate of bis-azoimine derivatives  $[A_1-A_6]$  with both cyclic anhydrides is slower than that of bisimine derivatives  $[B_1-B_5]$  with the same cyclic anhydrides, the reason may be due to the further conjugation with azo groups which leads to increase the stability of these bisimine derivatives and decrease the characteristic of  $\pi$  bond in (C=N) group, so the rate of reaction will be decreased.
- 3. The cycloaddition reaction between cyclic anhydrides and bisazoimine derivatives containing strong electron with - drawing group, such as nitro or chloro, in *p*- position to imine group never take place, the reason may be attributed to decrease the characteristic of  $\pi$ - bond in (C=N) group due to the further conjugation with nitro group and decreasing the electronic density of benzene ring in case of chlorine atom which leads to increase strength of the conjugation.
- 4. Four compounds appeared higher inhibithion against Gram- positive bacteria (*Staphylococcus aureous*), while only one compound showed higher inhibithion against Gram- negative bacteria (*Escherichia coli*), also seven compounds showed medium inhibition against the positive bacteria, while two compounds

appeared medium inhibition against the negative bacteria, moreover, seven compounds showed no inhibition against the positive bacteria, while fourteen compounds showed no inhibition against the negative bacteria. These results indicate that the synthesized bis-1,3-oxazepine compounds are more reactive against Gram- positive bacteria than the other.

## **Prospective studies**

- 1. Introducing the synthesized bis- azoimine derivatives in a cycloaddition reaction type  $[2+3\rightarrow 5]$  with soduim azide or organic azides to obtain new bis tetrazole derivatives.
- 2. Introducing the synthesized bis- azoimine derivatives in a cycloaddition reaction type  $[2+5\rightarrow7]$  with succinic anhydride to obtain new bis-1,3- oxazepane-4,7-dione derivatives.
- 3. Using the synthesized bis- azoimine derivatives as starting material for the synthesis of  $\beta$  Lactam derivatives via the reaction with chloroacetyl chloride.
- 4. Treatment of the synthesized bis-1,3- oxazepine derivatives with various primary amines or hydrazines to obtain new bis-1,3- diazepine derivatives.
- 5. Study the liquid crystalline properties of the synthesized bis-1,3oxazepine-4,7-dione derivatives.

## References

- S. Blumel, H. Knackmuss and A. Stolz, *App. And Env.Micr.* (2002), 68, 8, 3948.
- N. M. Rageh, N. M. Ismail and M. K. Dean, *Journal Analytical Sciences and Spectroscopy* (2004), 49, 4, 240.
- R.O. Norman, "Principle of Organic Synthesis", Nethuen and Co. LTD., (1968),428.
- **4.** M.H.Said. ph.D, Theses collage of Science Baghadad university (2007).
- 5. M. Chen and C. Liu, J. Chin. Chem. Soc. (1999), 4,6833.
- J. G. Smith," Organic Chemistry ", 2<sup>nd</sup> Ed, John Wiley and Sons New York, (2008), 986.
- H. Meislich, H. Nehamkin and J. Sharefkin,"Organic Chemistry", 4<sup>th</sup> Ed, Jr .Whitman Collage, New York, (1997), 409.
- 8. O. A. Adegoke and O. E. Umoh, *Acata Pharm* 2009,59, 407.
- 9. P. F. Gordon , and P. Gregory , "Organic Chemistry in Color"Springer-verlag, New York,(1983),876.
- M. Brierley, S. Carter, P. France and J. Pederson, *Electron. Lett.* (1990),26,329.
- 11. Y. M. Issa and B. E. El-Anadolu, Ind. J. of Chem (1983), 22, 386
- **12.** *H. Nishihara*, *Bull. Chem. Soc. Jpn.* (2004),77,407.
- L. Fedorov, M. Zhukov and A. Ermakov, *Izv. Akad. Nauk. SSSR*, *Ser. Khim*. (1984),35,1185.
- M. J. Hudson, "Partitioning Separation of Metal Ions Using Heterocycligands" University of Reading, United Kingdom ,(2001),987.
- 15. S. Ali, A. Nassar, N. Ibrahim and A. M. Khalil, *Ind. J. of Chem.* (1985),24, 537.

- **16.** I. Pate, K. Chikhlia and P. Desai, *Oriental J. Chem.* (1999),15,363.
- **17.** A. K. H. Shuwailiya, M.SC. Thesis College of Science University of Baghdad, (2000),10.
- P.Sykes, "A Guidebook to Mechanism in Organic Chemistry",6<sup>th</sup>Ed, Longman, (1985),268.
- **19.** F. A. Carey, " **Organic Chemistry** ", 7<sup>th</sup> Ed; New York, (2008),942.
- **20.** H. R. Maradiya and V. S. Patel, *J. Braz. Chem. Soc.* (2001),12 ,6,710.
- 21. T. M. Devlin, "Textbook of Biochemistry with clinical correlations ", 6<sup>th</sup> Ed, Bath Press. Avon, Great Britain, (2006),231.
- 22. K. M. Rathod and N. S. Thakre, *Chem. Sci. Trans* (2013), 2,1,25.
- 23. S.B. Desai, B. Desai and K.R.Desai, *Heterocycl. Commun*. (2001),7,83.
- 24. Y. Kalf, M.Sc. Thesis, *University* of Anber (2001), 12.
- 25. T. Bradshow, S. Wrigley and R. Schultz, *Brit. J. Cancer*, (1998)
  77, 745.
- V. Mkpenie, G. Ebong, I. B. Obot and B. Abasiekong, J. Org. Chem. (2008),5, 3, 431.
- 27. E. H. Mossalamy, Port. Electrochim. Acta (2009),27,143.
- **28.** M. A. Ashraf, K.M. Abdul Waji, *IPCBEE* (2011), 10,167.
- **29.** S. George, "Organic Chemistry", Mosby-Year Book, (1995), 589.
- 30. F. M. Menger, D. J. Goldsmith and L. Manden, "Organic Chemistry", 2<sup>nd</sup> Ed, Pergamon Press, New York, (1975),318.
- D. Gargiulo, N. Ikemoto, J. Odingo, N. Bozhkova T. Iwashita, N.Berova and K. Nakanishi, *J. Am. Chem.Soc*. (1994) ,116, 3760.
- 32. J. March, "Advanced Organic Chemistry ",Megraw-Hill, international book Co., John Wiley and Sons, New York, 4<sup>th</sup>ed,(1992), 896.
- **33.** K. F. Ali, Ph.D. Thesis, College of Education Ibn-Al-Haitham, University of Baghdad (2005),20.
- **34.** L. P. Hammett, " **Physical Organic Chemistry** ", Mc Graw, Hill Book Co., Inc. New York ,(1970) ,333.
- 35. P. R.S. Murray, "Principles of Organic Chemistry ", Amodern and comprehensive text for. Schools and colleges, Hermann Educational Books Ltd., London,2<sup>nd</sup>ed ,(1974) ,252.
- **36.** M. Verma, S. N. Pandeya, K. N. Singh and J.P. Stables, *Actapharm*. (2004) ,544,953.
- **37.** B. Baul, A. Linden and K. S. Singh, *Acta Cryst.* (2006) 62,2566.
- **38.** M.Zarei, and A. Jarrahpour, *I.J.S.T* (2011), 38,235.
- **39.** H. Dacker and P. Becker, *Ann. Chem.* (1913), 395, 362.
- 40. F. A. Hussein, Iraqi J. Chem. (2000),26,1,35.
- 41. F. A. Hussein, Iraqi J. Chem. (2000),26,1,42.
- 42. M.R. Snyder, R.B. Hasbrouck and J.F. Richardson, J. Am. Chem.Soc. (1939), 61, 3558.
- 43. D. S.Pratt, G. A. Perkines, *Chem. Abstr.* (1952) ,46 ,5005.
- 44. J. M. Naps, I. B .Johns, *Chem. Abstr.* (1948) ,42, 1571.
- **45.** Mark Cushman, Neal Castagnoli, *J. Org. Chem.* (1971), 36 ,22,3404.
- **46.** T. Atto and A. S. Al-Taay, "**Organic Chemistry** ", Higher Education Press, Baghdad, (1987), 65.
- **47.** F. A. Al-Rammahy, Ph. D. Thesis, College of Education Ibn-Al-Haitham, University of Baghdad (2005),16.

- **48.** A.Wasserman, "Diels-Alder Reactions", Elsevier, New York, (1965),133.
- 49. R. Huosgen, R. Grashey and J. Sauer, "The Chemistry of Alkene" (Ed. S. Patai), Interscience, New York, (1964), 739.
- 50. P. K. Kadaba and J. O. Edwards, J. Org. Chem. (1960),25, 1431.
- **51.** D.H. Deyrup and R.B. Grunewald, *Tetrahedron Letters* (1965),32.
- 52. H. Standinger, Ann. Chem. (1907), 356, 51.
- 53. G.K. Bckley, J.Chem.Soc. (1954),1850.
- 54. K. Alder, "Newer Methods of Preparative Organic Chemistry", Interscience, New York, (1948) ,504.
- 55. D. T. Mahmood, Ph. D. Thesis, College of Education Ibn-Al-Haitham University of Baghdad (2006),17.
- **56.** D. F.Hassan, M.Sc. Thesis, College of Education Ibn-Al-Haitham University of Baghdad (2007), 20.
- **57.** R. N. Jadeja, N.J.Parmar and J. R. Shah , *Iranian Polymer Journal* (2005),14, 11, 1008.
- Y.K. Gupta, S.C. Agrawal, S.P. Madnawat and R.Narain, *J.Res* .*Chem* (2012), 2,4, 68.
- A. Noureen, S.Saleem, T.Fatima, H.Masood and B. Mirza, J. Pharm. Sci (2013),26, 1, ,113.
- 60. A. A. Jarrahpour, M. Motamedifar, K. Pakshir, N. Hadi and M. Zarei, *Molecules*, (2004), 9, 815.
- A.W. Naser, H. T. Ghanemand A. M. Ali, J. of university of anbar for pure science 2010,4,3.
- 62. P. Phatak, V. Jolly and K. Sharma, *Orient. J. Chem* 2000,16,493.
- 63. F. A. Carey R. J. Sundbery, "Advanced Organic Chemistry ", 5<sup>nd</sup> Ed; Interscience ,New York , (2007), 243.
- **64.** T. W. Solomons and G. B. Fryhie, "**Organic Chemistry** ", 9<sup>th</sup> Ed; Wiley, New York, (2007), 995.

- 65. S. Sankararman and R. Hoffmann, "A Textbook of Pericyclic Reaction",1st Ed, Springer,New York (2005),216.
- 66. A. Miller and H. Philippa, "Writing Reaction Mechanisms in Organic Chemistry ", 2<sup>nd</sup> Ed, Benjamin, Inc., London, (1999),366.
- 67. J. H. Wosnick, A. Keating and M. S. Shoichet, Angew. Chem. Int. Wiley, (2007),6126.
- 68. O. Buchardt and B. Jensen, Acta Chem. Scand, (1968), 22, 3, 877.
- **69.** O. Tsuge, Kaji Oe and T. Ohnishi, *Heterocyclic*, (1982),19 9,1609.
- **70.** A. Th. Salem, Ph.D. Thesis, College of Science, Al-Nahrine University (2008),21.
- **71.** M. Ta. Tawfiq, ph.D. Thesis,College of Education Ibn Al-Haitham, University of Baghdad (2004),18.
- **72.** R. S. Jwad, M.Sc. Thesis, College of Education Ibn-Al-Haitham, University of Baghdad (2006).
- 73. A.Hameed, Journal of Al-Nahrain University 2012, 15, 4, 47.
- 74. S. A. Yousif, J. Baghdad for Sci (2013),10,3.
- 75. A. J. Mahrath, S. A. Aowda, S. N.Kamil, Journal of BablylonUniversity, pure and Applied Sciences (2013), 21, 1.
- 76. Z. H. Abood, Iraqi International J. of chemistry 2013,50,207.
- 77. A. V. samet, K. A.kisiyi, V. N .marshalkin, Y. A.strelenko, M.M.Raihstat, *Tetrahydron* (2008), 64, 51, 11763.
- 78. M. S. Jain, S. J. Surana, Arabian Journal of Chemistry 2013,7,33.
- **79.** J. Mikim, K. Y. Lee and J. N. kim, *Bull. Korean Chem.* (2002), 23,8,1055.
- 80. D. Gauthier and R. A. Rivero, J. Org. Chem. (1999), 64, 3060.
- S. Bilgic, M. Ozlem, M. Gunduz and N. Karakoc, *Arkivoc* (2009), 185,356.

- J. Jiu, S. Mizuba and J. Hribar, American Society For Microbiology(1977),33,1,26.
- 83. O. Levy, D. Varon, M. Erez and E. Keinan, *Bioorg. Med. Chem. Lett.* (2001),11, 2921.
- 84. G. P. Singh, Indian Journal of Psychiatry 2009,51,4,327.
- H. Fakhraian, Y. Nafary and H. Chalabi, *Res. Chem. Intermed* Springer (2009), 35, 355.
- G.Y Yeap, A.T Mohammad , H. Osman, Journal of Molecular Structure (2010), 98, 233.
- 87. F.Aiello, A.Brizzi, A.Garofalo, F.Grande and N.Neamati, *Bioorg.&Mid. Chem.* (2004),12,189.
- M.H.Serrano-Wa , D.R.Laurent ,Y.Chen, S.Huang, K.R.Lay and T.M.Stickle, *BioOrg.&Med.Chem.Lett.* (2002), 12, 19, 2757.
- X.H. Liu, Y.M. Jia, B.A. Song, Z.X.Pang, S. Yang, *Bioorganic & Medicinal Chemistry Letters* (2013),23,720.
- 90. X.G. Deng, C.X. Wei, F.N.AnLi, Z.G.Sun, Z.S.Quan, European Journal of Medicinal Chemistry (2010), 45,3080.
- 91. M. K. seennaiah, A. kunar, C. R. Reddy, S. K.mamidjala, *Tetrahydrone letters* (2011),52, 16,806.
- 92. A. I. Vogel, "A text book of Practical organic chemistry ", 3rd, Longman group limited ,London, (1973), 622.
- 93. B. S. Bahl; "A testbook of Organic Chemistry" 4<sup>th</sup> Ed, New York, Wiley, (2007),328.
- 94. L. D. Field, S. Sternhell and J. R. Kalman; "Organic Structure from Spectra", 4<sup>th</sup> Ed, plenum press. New York, (2007),243.
- 95. D.H.Williams, I.Fleming, "Spectroscopic method in Organic Chemistry",2nd., McGraw-HillBook Co.Limited,London,(1973), 771.

- 96. W. H. Brown, C. S. Foote and B. L. Iverson,"Organic Chemistry", 5<sup>th</sup> Ed, prentice- Hall, Inc. NewYork (2009),654.
- 97. H. H.Eissa, Jouraal of Current researchin Science, (2013),1, 2, 96.
- 98. S. A. Saoud, Ibn AL- Haitham J. For Pure& APPL. SCI (2011),24,1.
- 99. F. A. Carey and R. J. Sundberg, "Advanced Organic Chemistry", 5<sup>th</sup> Ed; Springer, NewYork (2007),358.
- 100. Z. H. Abood, Ph. D. Thesis, College of Science, University of Babylon (2007).
- 101. A. M. Asiri and K. O. Badahdah, *Molecules* (2007),12, 1796.
- 102. L. G. Wade,"Organic Chemistry", 7<sup>th</sup> Ed; Inter Science, New York (2010),765.
- 103. A. Rahman and M. Choudhary; "Solving problems with NMR Spectroscopy", 1991.
- 104. R. M. Silverstein, F. X. Webster and D. J. Kiemle, "Spectrometric Identification of Organic Compounds", John Wiley and Sons Inc, New York, (2005),956.
- 105. R. C. Dubey and D. K. Maheshman,"ATextbook of Microbiology", 2<sup>nd</sup> Ed, McGraw-Hill Companies, (2005),1123.
- 106. J. Jeong, C. L. Chang, T. S. Park and S. R. Kim, J. Korean Med. Sci. (2002), 17, 168.
- 107. I.N. Okoke and J. Kanack , J. Clin. Microbiol (2002),40,1, 301.

## الخلاصة

تم من خلال هذا العمل تحضير سلسلتين جديدتين من مشتقات ثنائية الازوثنائية [ ،3- اوكسازبين-4،7- دايون [A<sub>7</sub>-A<sub>18</sub>] ومشتقات ثنائية [,3,3- اوكسازبين- 4،7- دايون [B<sub>6</sub>-B<sub>15</sub>] وذلك بأستعمال تفاعل الاضافة الحلقية [2+5] لانهدريدات الفثالك و الماليك الى بعض الايمينات الثنائية الحاوية على مجموعتي أزو [A<sub>1</sub>-A<sub>6</sub>] والايمينات الثنائية [B<sub>6</sub>-B<sub>15</sub>] المحضرة .

تم في الخط الأول من البحث تحويل مركب اورثو - توليدين إلى مشتق ثنائي ألاز والديهايد [A]وذلك من خلال تفاعل الازدواج مع ايون الفينوكسيد السالب لمركب 2- هيدروكسي بنز الديهايد. ان تكاثف مجموعتي الالديهايد في مشتق الأز والديهايد الثنائي المحضر [A] مع مجموعتي أمين في امينات اولية متنوعة ومشتق هيدرازين واحد (سايكلو هكسيل امين ,فنيل هيدرازين ,4,2 ثنائي مثيل انيلين,4 - ميثوكسيإنيلين, انيلين,4 - بروموانيلين) بوجود حامض الخليك الثلجي كعامل مساعد في الأيثانول المطلق أدى إلى تكوين مشتقات الاز وايمين الثنائية -[A] مقابق الثلاجي كعامل مساعد في الأيثانول المطلق أدى إلى تكوين مشتقات الاز وايمين الثنائية -[A] مشتقات الاز وايمين الثنائية المحضرة [A] من الخليك الثلجي كامل مساعد في الأيثانول المطلق أدى إلى تكوين مشتقات الاز وايمين الثنائية [A] على التتالي تم إدخال مشتقات الاز وايمين الثنائية المحضرة [A] في تفاعل إضافة حلقية [2+5] مع كل من انهدريد الفثالك وانهدريد ألماليك في البنزين الجاف فتم الحصول على مشتقات 1،3- اوكساز بين -7,4 - دايون ثنائية جديدة حاوية في تركيبها على مجموعتي أزو -A] مشتقات [A] م المان الخالي وكما موضح في مخطط (I).

تم في الخط الثاني من البحث تحضير مشتقات ايمين ثنائية  $[B_1-B_5]$  عن طريق التكاثف المباشر بين اورثو - توليدين ومشتقات بنز الديهايد متنوعة (5،2- ثنائي ميثوكسي بنز الديهايد,4-كلور وبنز الديهايد, بنز الديهايد,2- هيدر وكسي بنز الديهايد,4- N,N-4-ثنائي مثيل أمينو بنز الديهايد) على التتالي بوجود حامض الخليك الثلجي كعامل مساعد في الايثانول المطلق. تم إدخال مشتقات الايمين الثنائية المحضرة  $[B_1-B_5]$  لاحقا في تفاعل إضافة حلقية [2+5] مع كل من انهدر يدالفثالك وانهدريد الماليك في البنزين الجاف فتم الحصول على مشتقات ا.3- وكل من انهدريدالفثالك ثنائية جديدة  $[B_6-B_{10}]$  و  $[B_{10}-B_{15}]$  على التتالي وكما موضح في مخطط (II).

تم تشخيص جميع مركبات الأوكسازبين [A7-A18] و[B6-B15] المحضرة بوساطة التحليل الكمي العنصري الدقيق (C.H.N.) وكذلك بالطرق الطيفية المتضمنة مطيافية الأشعة تحت الحمراء وتم تشخيص مركبات الأوكسازيين [A7, A8, A9, A10, A11, A13, A14, A15, A16, A17] و . <sup>1</sup>H NMR بمطيافية الرنين النووي المغناطيسي للبروتون  $[B_7, B_8, B_{11}, B_{12}, B_{13}, B_{15}]$ 

تضمت الخطوة الأخيرة من البحث تقييم أولي للفعالية ضد البكتريا لجميع المركبات النهائية [A7-A18] و[B6-B15] و[B6-B15] والتي اختبرت فعاليتها ضد بكتريا (Staphylococcus aureous) الموجبة لصبغة كرام وبكتريا (Escherichia coli) السالبة لصبغة كرام. تم تعيين هذه الفعاليات خارج الجسم باستعمال طريقة الانتشار في الوسط الغذائي (الاكار). دلت النتائج المستحصلة بأن بعض المركبات أظهرت فعالية عالية وكما موضح في جدول (7-3).





